



Advances in TRP channel drug discovery: from target validation to clinical studies

Ari-Pekka Koivisto¹, Maria G. Belvisi^{2,3}, Rachele Gaudet⁴ and Arpad Szallasi⁵✉

Abstract | Transient receptor potential (TRP) channels are multifunctional signalling molecules with many roles in sensory perception and cellular physiology. Therefore, it is not surprising that TRP channels have been implicated in numerous diseases, including hereditary disorders caused by defects in genes encoding TRP channels (TRP channelopathies). Most TRP channels are located at the cell surface, which makes them generally accessible drug targets. Early drug discovery efforts to target TRP channels focused on pain, but as our knowledge of TRP channels and their role in health and disease has grown, these efforts have expanded into new clinical indications, ranging from respiratory disorders through neurological and psychiatric diseases to diabetes and cancer. In this Review, we discuss recent findings in TRP channel structural biology that can affect both drug development and clinical indications. We also discuss the clinical promise of novel TRP channel modulators, aimed at both established and emerging targets. Last, we address the challenges that these compounds may face in clinical practice, including the need for carefully targeted approaches to minimize potential side-effects due to the multifunctional roles of TRP channels.

In 1969, a *Drosophila* mutant with defective light sensing was identified, which showed only a transient receptor potential (TRP) when exposed to continuous light instead of the expected sustained response¹. This was later found to be caused by the lack of a functional copy of the gene coding for an ion channel, which was named *trp*². However, the name ‘TRP’ channel is really a misnomer as the wild-type channel in fact causes a persistent (and not transient) current. This behaviour of TRPs is in contrast to many ion channels, which fully adapt when exposed to constant stimulation.

TRPs are multifunctional signalling molecules, expressed in many tissues and cell types^{3,4}. Most TRPs are polymodal channels, so-called coincidence detectors that are activated by both physical (temperature, voltage, pressure and tension) and chemical stimuli⁵. Beyond that, few generalizations can be made about TRP channels. Some TRPs function as non-selective cation channels in the plasma membrane; others regulate Ca²⁺ release in intracellular organelles.

The mammalian TRP channel superfamily has 28 members (27 in humans)³. On the basis of sequence homology, the superfamily is divided into six subfamilies: canonical (also known as short TRPs, TRPC1–7), vanilloid (also known as TRP channel subfamily V, TRPV1–6), melastatin (also known as TRP channel subfamily M,

TRPM1–8), ankyrin (also known as TRP channel subfamily A, TRPA1), mucolipins (TRPML1–3), and polycystins (also known as polycystic kidney disease 2-like 1 protein (PKD2L1, also termed TRPP3) and polycystin-2 (TRPP2))^{3,4}. Because these subfamilies were created based on sequence homology and not function, members often have little in common. For example, TRPM2 is a redox sensor in macrophages⁵; TRPM7 provides a major Mg²⁺ uptake pathway in intestinal epithelial cells⁶; and TRPM8 detects cold and menthol in sensory neurons^{7,8}, but regulates epithelial growth in response to androgens in the prostate⁹. Despite the structural similarities shared by these proteins (FIG. 1; BOX 1), there are enough differences to develop subtype-selective compounds.

Most TRPs have restricted expression patterns, but their varied tissue distribution means that the superfamily affects most cells, tissues and organs of the human body. Overall, the diverse physiological functions and regulatory mechanisms of TRPs affect how they are implicated in disease. These include both genetic and acquired channelopathies, as well as many disorders in which targeting one or more TRP channel could alleviate symptoms or provide therapeutic effects¹.

Most TRPs are subjects of intensive drug discovery and development efforts. In this Review, we summarize the crucial advances of the past decade in our

¹R&D, Neurological Disorders Research, Orion Pharma, Turku, Finland.

²Research & Early Development, Respiratory & Immunology BioPharmaceuticals-R&D, AstraZeneca, Gothenburg, Sweden.

³Respiratory Pharmacology Group, Airway Disease, National Heart & Lung Institute, Imperial College London, London, UK.

⁴Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, USA.

⁵1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

✉e-mail: szallasiarpad@gmail.com

<https://doi.org/10.1038/s41573-021-00268-4>

Coincidence detector

A process by which a neuron can detect and converge separate signals into one input (such as an action potential).

Gustatory sweating

Perspiration in the head-and-neck area after eating hot spicy food.

understanding of the complex roles that TRPs have in the development and progression of human disease. Whereas our improved understanding of the structures of TRP channels will undoubtedly aid drug discovery (BOX 1), the increasingly diverse physiological roles of TRPs pose a serious challenge to drug development. Indeed, it has proved difficult to obtain sufficient specificity for clinically useful intervention without unacceptable side effects. Although developing clinically useful TRP modulator drugs is challenging, the potential rewards are enormous given the pathogenic role of TRPs in chronic pain, neurology, oncology, dermatology, pulmonology, cardiology, urology and rare diseases.

TRP channel biology and pathology

Although all TRP channels are evolutionarily highly conserved, their sensitivity to external stimuli show striking species-related differences. For example, TRPV1 is activated by capsaicin in mammals (it was originally cloned as the ‘capsaicin receptor’)¹⁰, but not in birds¹¹. However, changing position 578 in the S4/S5 helix of *cTrpv1* from alanine to glutamine renders the chicken receptor capsaicin-sensitive¹². TRPV1 also shows distinct, species-dependent, heat-activation thresholds, and so TRPV1 is a noxious heat sensor in some mammals (including humans)¹³ but not in others (for example, camels that have evolutionarily adapted to desert heat)¹⁴. Similarly, the sensitivity of TRPA1 to cold differs between rodents and primates¹⁵. These species-dependent differences in channel sensitivity and function should be considered when selecting experimental animal models and interpreting the results.

TRPV1 is a prime example of diversity in TRP channel expression and function. TRPV1 is highly expressed

on primary sensory neurons as a major integrator of painful stimuli (afferent function) and a key initiator of neurogenic inflammation (efferent function)¹⁶ (FIG. 2). Moreover, TRPV1-expressing sensory neurons have been implicated in warmth sensing^{17,18} and itching¹⁹. In the viscera, neuronal TRPV1 triggers reflex pathways like cough, emesis, heart rate, micturition and intestinal peristalsis¹⁶. Albeit at much lower levels, TRPV1 is also expressed in various brain nuclei²⁰ and in non-neuronal cells²¹.

TRPV1 is unique among drug targets in that its initial excitation by agonists is followed by a lasting refractory state (traditionally referred to as desensitization) in which TRPV1-expressing neurons are not responsive to both a repeated capsaicin challenge and to various unrelated stimuli¹⁶ (FIG. 2).

The role of TRPV1 in thermoregulation is well established^{22,23}. In rodents, activation of TRPV1 with capsaicin initiates heat-loss behaviour at warm ambient temperatures (30–32.5 °C) and mice exhibit ‘red ear’ caused by vasodilation and seek the cool surface of the cage¹⁶. By contrast, TRPV1-deficient (*Trpv1*^{-/-} or capsaicin-desensitized) mice display deficiencies in heat-loss mechanisms (such as body licking) and develop hyperthermia when exposed to 35 °C (REF.²⁴). In humans, capsaicin may cause gustatory sweating as a mechanism of heat loss¹⁶, whereas TRPV1 antagonists can increase or decrease body temperature, or even leave it unchanged (‘thermoneutral antagonists’)^{25–27}. These thermoregulatory side effects can be exploited for pharmacotherapy: TRPV1 antagonists that cause hyperthermia as a dose-limiting, on-target adverse effect may also help to restore normal body temperature after medical cooling^{28,29}. In turn, TRPV1 agonists




Fig. 1 | Similarities and differences between the structures of TRP channels. Representative structures for each TRP channel subfamily, coloured to highlight common structural features. The S1–S4 (gold) and the S5 and S6 pore domains (cyan) are the only domains common to all subfamilies. The TRPA, TRPV, TRPM, TRPC and TRPN channels have TRP box helices (dark green). The TRPA, TRPC, TRPN and TRPV channels have amino (N)-terminal cytoplasmic ankyrin repeats (violet; the TRPA1 structure is missing about 11 repeats, as indicated by the question mark and violet shapes). The TRPC, TRPM and TRPN channels have a homologous pre-S1 helical linker (lilac) and C-terminal re-entrant loop and rib helix (brown), which is followed by a coiled

coil in the TRPC and TRPM channels (blue; TRPA channels also have a carboxy (C)-terminal coiled coil). The melastatin homology regions (MHRs) of TRPM channels are shown in tan, and the NUDIX domain unique to TRPM2 is shown in red. The TRPML and TRPP channels have a homologous lumenal domain (dark grey). The pre-S1 linkers of the TRPV and TRPA channels and the C-terminal region of the TRPV channels (light grey) share no clear homology outside their respective subfamilies. The structures depicted are human TRPA1 (PDB ID 3J9P), human TRPC3 (PDB ID 6CUD), human TRPM2 (PDB ID 6MIX), *Drosophila* TRPN (NompC; PDB ID 5VKQ), human TRPP2 (PDB ID 5T4D), human TRPML1 (PDB ID 5JW5) and rabbit TRPV2 (PDB ID 6OO3).


Box 1 | Emerging features in TRP channel structures

Effective drug discovery targeting individual TRP channels will need in-depth knowledge of the druggable structural sites and the activation and inactivation mechanisms. This, in turn, requires high-resolution structures in multiple states combined with functional studies. However, drug discovery strategies can also be conceptually enhanced by leveraging the rapidly multiplying structural information to take a bird's-eye view of the whole family.

With at least one structure available for each subfamily, we can now identify several recurring structural features. As predicted from their sequence homology to voltage-gated channels, all TRP channels have the S1–S4 transmembrane segments that form peripheral sensing domains (yellow in FIG. 1), whereas S5 and S6 tetramerize to create a central pore (cyan in FIG. 1). Other recurring structural features became apparent from sequence analyses, such as the ankyrin repeats in the N-terminal cytosolic domains of the TRPA, TRPC, TRPV and nonmammalian TRPN channels²⁹³ (pink in FIG. 1). Moreover, the TRP box, a sequence motif first detected in the TRPC, TRPM and TRPV channels, forms a helix parallel to the membrane (green in FIG. 1). This helix, which is a link between the cytosolic and transmembrane domains, is actually found in all TRP subfamilies except TRPML and TRPP.

Additional unanticipated homologous structural features are shared between the TRPC, TRPM and nonmammalian TRPN channels. In the BOX 1 figure below, these shared features are viewed from above the membrane to better visualize their common structural fold, with the green TRP box helix included for reference. First, the approximately 150 N-terminal residues preceding the transmembrane domain (lilac) form a cytosolic helical platform and a re-entrant loop that penetrates the inner leaflet of the membrane near the S1–S4 domain. Second, the approximately 80–100 C-terminal residues following the TRP box helix (green) also form a re-entrant loop followed by a long helix parallel to the membrane plane (brown). This long helix, named the 'rib helix' in TRPM channels²⁹⁴, 'connecting helix' in TRPC channels²⁹⁵ and 'CH2' in TRPN channels²⁹⁶, is then followed by a coiled coil in TRPC and TRPM channels (blue).

Shared structural features between TRP channel subfamilies like the ones described here suggest shared regulatory mechanisms. Thus, information gained in individual subfamilies can and should be mined to advance our understanding of channels from other subfamilies with similar structural features.



that cause hypothermia may protect the brain after stroke³⁰. As reviewed elsewhere^{16,22,23}, there is no consensus in the literature as to the exact anatomic site of the TRPV1-expressing thermoregulatory centre, or the mechanism by which it regulates body temperature.

Cryo-electron microscopy and X-ray crystallography have provided novel insights into TRP channel structure and function and highlighted several druggable sites (FIG. 3). TRPV1 has fourfold symmetry with different pore profiles for ligand-bound structures³¹, and a vanilloid-binding pocket deep within the membrane bilayer³² (FIG. 3b,f). TRPA1 is a sentinel for electrophilic irritants and has a distinct allosteric nexus where a covalent modification of cysteine residues regulates channel activity³³ (FIG. 3c). Indeed, all known synthetic TRPA1 antagonists, such as A-967079, act as negative allosteric modulators (FIG. 3b). This is important because they can block TRPA1 (over)activation, and yet leave some level of physiological activity intact, in contrast to traditional orthosteric antagonists.

Epigenetic regulation of TRPs is an emerging area of research. In rats, histone H3 acetylation at the *Trpv1* promoter region leads to increased TRPV1 protein expression in sensory neurons with concomitant visceral hyperalgesia³⁴. In mice, SUMOylation protects TRPV1

from metabolic damage during experimental diabetes and thus delays the development of neuropathic pain³⁵. TRPV1 from human donor tissue is also SUMOylated³⁵. Likewise, methylation of the human *TRPA1* promoter region can result in increased TRPA1 levels and altered pain perception³⁶. Indeed, *TRPA1* gene methylation is dysregulated in patients with Crohn disease, contributing to visceral pain³⁷.

Genetic defects in TRPs — or TRP channelopathies — are increasingly recognized causes of hereditary human disease⁴. For example, TRPV4 channelopathy³⁸ is linked to at least nine different diseases, ranging from autosomal dominant brachyolmia type 3 to Charcot–Marie–Tooth neuropathy type 2. Furthermore, polymorphisms in TRP genes may regulate disease risk, as exemplified by the reduced migraine incidence in carriers of rs10166942, which correlates to reduced *TRPM8* gene expression³⁹.

Pain: TRP channels as analgesic targets

Medical control of chronic pain is frequently unsatisfactory, and the current therapeutic pain market remains dominated by agents that have been around for decades. Narcotics (opioids) are effective painkillers, but, acting in the brain, they are also addictive. A logical strategy to

Allosteric nexus

A substructure in a protein that serves as a shared regulatory site, binding to chemical ligands or responding to physiological stimuli, and resulting in changes in the shape and activity of the protein.

SUMOylation

Covalent modification by the small ubiquitin-related modifier peptide.

Brachyolmia type 3

A form of severe skeletal dysplasia characterized by an abnormal curve of the spine (kyphoscoliosis) and flattened cervical vertebrae.

Charcot–Marie–Tooth neuropathy type 2

A genetic defect that causes decreased heat, cold and touch sensations mostly in the hands and feet owing to axon damage.




Fig. 2 | TRPV1 in the pain pathway: similarities and differences between desensitization by agonists and blockade by antagonists. TRPV1 is expressed on primary sensory neurons of the unmyelinated (C fibre) type. Activation of TRPV1 by agonists like capsaicin, heat and protons (and putative ‘endovanilloids’) triggers the release of pro-inflammatory neuropeptides like substance P (SP) and calcitonin gene-related peptide (CGRP), thereby initiating the biochemical cascade known as neurogenic inflammation. At the same time, an impulse is generated that is perceived in the brain as pain or itching. Protein kinase C (PKC) and nerve growth factor (NGF) lower the activation threshold of TRPV1 (sensitization). Stimulation of TRPV1 with a therapeutic dose of capsaicin results in a lasting (up to months) but fully reversible state in which the previously excited neurons remain unresponsive (‘silent’) to further challenge; traditionally, this is called desensitization. High-dose capsaicin patches and site-specific injections

relieve pain by this mechanism. There is an ill-defined line between reversible desensitization and irreversible neurotoxicity achieved by therapeutic and supratherapeutic doses of capsaicin, respectively. Although both desensitization and neurotoxicity depend on capsaicin-induced Ca²⁺ influx through the TRPV1 channel, the downstream molecular mechanisms are still poorly understood. Mitochondrion swelling is an early ultrastructural sign of capsaicin neurotoxicity. Ca²⁺ is thought to sequester in mitochondria, where it triggers apoptosis using a molecular pathway that includes caspase activation. Intrathecal resiniferatoxin is used as a ‘molecular scalpel’ to achieve permanent analgesia in cancer patients with chronic, intractable pain by ablating sensory neurons. In principle, a similar strategy can be used to kill cancer cells that overexpress TRPV1 compared with normal counterparts. We note that small molecule TRPV1 antagonists prevent only TRPV1 activation by agonists, leaving other pain sensors intact.

avoid opioid side effects is to target the beginning of the pain pathway: the nociceptor where pain is generated^{25,40}. Hence there is tremendous interest expressed by pharmaceutical companies in TRP channels that detect noxious stimuli in the periphery (FIG. 4).

The ‘capsaicin receptor’, TRPV1. Desensitization to capsaicin has a clear therapeutic potential (FIG. 2). Indeed, high-dose capsaicin patches^{41,42} and site-specific injections⁴³ are clinically proven to provide meaningful pain relief in patients with osteoarthritis, post-herpetic neuralgia and diabetic polyneuropathy. Peripheral expression of TRPV1 on nociceptive fibres is predictive of the patient’s response to capsaicin therapy, which may explain the discrepant outcome in clinical trials with capsaicin in patients with diabetic polyneuropathy in whom nociceptive fibres often degenerate during advanced disease⁴⁴.

Capsaicin evokes an intense initial pain reaction that limits the dose that patients can tolerate¹⁶. To reduce this adverse effect, ‘non-pungent’ TRPV1 agonists like olvanil (NE19550)⁴⁵ and MRD-652 (REF.⁴⁶) have been developed that differ from capsaicin in the activation kinetics of the receptor. These compounds showed promise in animal models of pain^{45,46}, but their clinical value remains to be demonstrated.

The ultrapotent capsaicin analogue, resiniferatoxin, is undergoing clinical trials as a ‘molecular scalpel’ with which to achieve permanent analgesia in severe osteoarthritic pain^{47,48}, and in cancer patients with chronic intractable pain⁴⁹. This approach has already succeeded in the veterinary clinic, in which intrathecal resiniferatoxin provided lasting pain relief and restored ambulation in dogs with osteosarcoma⁵⁰. Resiniferatoxin has been tested in a small number of female patients with cervical cancer metastatic to pelvic bone, and the results are promising so far⁵¹.

Because TRPV1 agonists that cause desensitization can be perceived as functional antagonists of the receptor (FIG. 2), it has been postulated that small molecule TRPV1 antagonists can be also pursued as therapeutic agents^{25,52,53}. Indeed, TRPV1 is a highly druggable target⁵². Various antagonist chemotypes have been discovered, and many have matured into clinical lead molecules^{25,52,53}. The efficacy of TRPV1 antagonists in preclinical pain models varied; some showed efficacy in both inflammatory (for example, complete Freund adjuvant-induced arthritic pain) and neuropathic pain models (such as the Chung model), whereas others were active only in the inflammation models^{25,53}. We note that both the magnitude of the analgesic effect and the dose needed to demonstrate efficacy varied.

Freund adjuvant-induced arthritic pain
A frequently used rodent model for screening analgesics against inflammatory pain induced by local injection of dead mycobacteria.

Chung model
A frequently used model for analgesic screening against neuropathic pain induced by unilateral spinal nerve ligation.

When using hypothermia by capsaicin as an on-target engagement model, many TRPV1 antagonists actually caused the opposite effect, hyperthermia²⁵. However, this febrile reaction could be managed with simple antipyretic agents like acetaminophen and disappeared upon repeated dosing, paving the way to studies in human volunteers⁵⁴. Since *Trpv1*^{-/-} mice are less responsive to noxious heat^{55,56}, and rodents desensitized to capsaicin show dramatically increased noxious heat threshold in the hot plate test¹⁶, it was unsurprising that TRPV1 antagonists impaired the cutaneous noxious heat sensation in humans, leading to burn injuries as a common adverse effect⁵³.

Owing to these unacceptable on-target adverse effects, many first-generation TRPV1 antagonists were

withdrawn from clinical trials: some, like AMG517, because of febrile reactions⁵⁷ and others, like MK2295, because of the burn injuries⁵⁸. Some antagonists that progressed into phase II efficacy trials failed to demonstrate analgesic activity, such as a terminated trial of AZD1386 for osteoarthritic pain⁵⁹. Other clinical trials were terminated without explanation, such as those sponsored by Sanofi/Glenmark (GRC-6211) and PharmEste (PHE575). Since functional TRPV1 expression on nociceptors predicts the patient's response to agonist (capsaicin) treatment⁴², one may argue that TRPV1 antagonist trial participants should also be selected on the basis of their capsaicin sensitivity. It is also worth mentioning that vitamin D was recently shown to act as a partial agonist of TRPV1 at physiologically relevant free plasma concentrations⁶⁰.




Fig. 3 | Structural information on ligand and drug binding by TRP channels, and gain-of-function mutations. Protein colouring is the same as in FIG. 1. **a–d** | Schematic descriptions of TRPV (**a**), TRPA1 (**b**), TRPM (**c**) and TRPML1 (**d**) illustrate the general binding site locations identified in structural findings of TRP channels. Similar ligand shapes indicate similar ligand-binding site locations in the respective proteins, and example ligands are labelled. Black stars indicate mutations associated with human diseases that are located at

the elbow connection between the S4–S5 linker and the S5 helix, and magenta stars in the S6 helix pore gate indicate mutations that lead to hypersensitive or constitutively active channels and gain-of-function phenotypes. Grey stars mark the TRPM2 D543E hypoactive mutation. **e** | Sample ligand-binding sites from the antagonist capsazepine bound to rat TRPV1 (PDB ID 5J50). **f** | Co-agonists PIP₂, Ca²⁺ and icilin bound to *Ficedula albicollis* TRPM8 (PDB ID 6NR3). **g** | Agonist ML-SA1 bound to human TRPML1 (PDB ID 6E7Z).




Fig. 4 | The pain pathway: wide expression of TRP channels in sensory neurons, skin and brain. Several TRP channels in free nerve endings or sensory corpuscles of sensory neurons transduce painful thermal (TRPV1, TRPA1, TRPM8 and TRPM3), chemical (TRPA1) and mechanical (TRPC1, TRPC3, TRPC6, TRPA1, TRPV2 and TRPV4) stimuli into electrophysiological excitation. TRP channels that do not participate in physiological sensation, but are recruited under pathophysiological conditions (for example, TRPC5 in mechanosensation) are of particular interest. TRP channels in keratinocytes, satellite glia and Schwann cells (TRPV1, TRPA1) also participate in transduction of painful stimuli. TRP channels in the central terminals of sensory neurons amplify and modulate neurotransmitter release in the spinal cord. TRP channels in the brain play critical parts in several physiological processes. It is likely that different TRP channels in the brain have different roles in acute nociceptive versus maladaptive chronic pain. Pain representation in the brain shifts from from nociceptive circuits in acute pain (left brain scan) to emotional circuits during chronic pain in functional magnetic resonance imaging (middle and right brain scans). Therefore, an assessment of central action or peripheral restriction of a TRP channel modulator needs to be carefully performed to maximize efficacy and therapeutic window.

A partial agonist can either act as an agonist or antagonist, depending on the presence of other ligands. Such effects may contribute to the variability of TRPV1 antagonists in clinical trials.

Although these problems tempered expectations, and many companies abandoned TRPV1 as an analgesic target, there have been a few promising developments. For example, the second-generation molecule, JNJ-39439335 (mavatrep), showed significant improvement versus placebo in stair climbing-induced clinical pain in participants with knee osteoarthritis⁶¹. Another compound, NEO6860, also showed an analgesic trend, although it did not statistically outperform placebo, without affecting body temperature or heat pain perception⁶². It remains to be seen whether these molecules — or other ‘thermoneutral’ antagonists, like GRTE16523 (REF.⁶³) — can demonstrate meaningful analgesic activity in the clinic. Ultimately, it will probably be easier to dissociate beneficial heat sensing from therapeutic inhibition of TRPV1 activity by targeted antagonist delivery because most, if not all, inhibitors of TRPV1 activation will inhibit heat sensing.

The role of TRPV1 phosphorylation by protein kinase-C (PKC) in the development of inflammatory hyperalgesia is well established⁶⁴. Eliminating the PKC phosphorylation site S801 by CRISPR/Cas9 editing in TRPV1 reduced the ongoing pain caused by masseter muscle inflammation without blocking physiological TRPV1 functions⁶⁵. This observation raises the possibility of engineering novel TRPV1 antagonists that selectively interact at the phosphorylated TRPV1.

As to future clinical testing, a promising indication for TRPV1 analgesia is gout. In experimental animals, urate crystals activate TRPV1, and the resultant pain is blocked by both genetic inactivation (*Trpv1*^{-/-} mice) and pharmacological blockade (SB-366791)⁶⁶. In a mouse model of gout arthritis, eucalyptol reduced both inflammation and pain by preventing the urate-induced up-regulation of TRPV1 expression in ankle tissues⁶⁷. Furthermore, SB-366791 attenuates dental pain in rats⁶⁸, and, as an added benefit, prevents alveolar bone loss in a rat model of periodontal disease⁶⁹. Other potential indications with increased *TRPV1* mRNA levels include endometriosis⁷⁰ and chronic lower back pain⁷¹. However, because much of the earlier preclinical efficacy data that predicted clinical value in inflammatory pain (such as osteoarthritic pain) did not translate in patients, caution is advised for these new potential indications.

The chemical nocisensor, TRPA1. *TRPA1* gene variants have been linked to paradoxical heat (painful cold) sensation⁷², sickle cell pain crisis⁷³, carbamazepine-responsive cramp-fasciculation syndrome⁷⁴, and familial episodic pain syndrome (FEPS)⁷⁵. FEPS is a gain-of-function TRPA1 channelopathy that causes debilitating upper body pain due to increased inward currents in response to TRPA1 channel activation at normal resting potentials. From a clinical perspective, this observation is not easy to interpret as patients carry both mutant (human *TRPA1* N855S) and wild-type alleles. TRPA1 is a tetramer and it is reasonable to assume that

CRISPR/Cas9 editing

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) is a technology that allows genetic material to be added, removed or altered by creating a ‘guide’ RNA to target specific DNA sequences.

Carbamazepine-responsive cramp-fasciculation syndrome

Peripheral nerve hyperexcitability syndrome that presents with stiffness, muscle pain, cramps and exercise intolerance.

Familial episodic pain syndrome

(FEPS). Rare genetic peripheral neuropathy disorder characterized by recurrent, intense upper body or lower limb pain in response to fatigue, fasting, physical stress or cold exposure.

patients express various mixtures of normal and mutant channels⁷⁶. Although one cannot predict the properties of these heteromultimers, the N855S mutation, like the analogous gain-of-function mutations in *TRPV4* and *TRPM4*, is in the linker that moves during channel gating (FIG. 3b–d), explaining how it causes channels to open more readily. An antagonist that selectively blocks the mutant FEPS protein would be optimal, but companies are unlikely to invest resources into such a small market.

Genetic deletion or pharmacological blockade of TRPA1 vastly attenuate responses to many harmful chemical stimuli, ranging from formaldehyde, through acrolein (present in cigarette smoke) and diesel exhaust, to tear gases^{77,78}. Moreover, endogenous compounds like methylglyoxal^{79,80} (a product of aberrant glucose metabolism) and reactive oxygen species (ROS) and nitrogen species all converge on TRPA1 (REF.⁸¹): these electrophilic compounds can activate the channel after covalently modifying a hypersensitive cysteine in the cytoplasmic domain of TRPA1 by electrophilic attack⁸² (FIG. 3c).

The temperature (cold) sensitivity of TRPA1 is subject to much debate and will not be discussed here, except to mention that *Trpa1*^{-/-} mice show attenuated cold allodynia evoked by anticancer drugs like oxaliplatin⁸³, and by ischaemia and reperfusion injury of the rodent hindlimb, a murine model of complex regional pain syndrome type I (CRPS-I)⁸⁴. Importantly, TRPA1 antagonists recapitulated the effects of genetic *Trpa1* inactivation⁸⁴, indicating a novel therapeutic strategy in CRPS-I patients. *Trpa1*^{-/-} mice also displayed reduced visceromotor responses to colorectal distension⁸⁵, indicating a role for TRPA1 in mechanical pain; and *Trpa1*^{-/-} rats showed decreased pain behaviours in response to chemical agonists of TRPA1, but normal responses to other pain stimuli, including cold, and itching⁸⁶. Animal studies with TRPA1 antagonists (such as A-967079, HC-030031 and AMG0902) suggested therapeutic potential in patients with neuropathic pain⁸⁷.

We note that CHEM-5861528, when given with streptozotocin to rats, ameliorated the pain and reduced the loss of intraepidermal nerve fibres⁸⁸. If these results were to be confirmed in diabetic patients, this observation suggests that TRPA1 antagonists can be disease-modifying by preventing (or at least delaying) the development of diabetic polyneuropathy.

As of today, only one TRPA1 antagonist has completed phase II clinical trials, Glenmark's GRC17536⁸⁹. Although GRC17536 significantly reduced pain scores in the non-denervation group of patients with painful diabetic polyneuropathy without worrisome side effects, the compound had problems with bioavailability/pharmacokinetics and did not progress into phase III. Topical administration may help overcome such problems. Indeed, a topical HC-030031 gel (0.05%) reversed mechanical and cold allodynia in mice after ultraviolet B-induced burn injury⁹⁰. This implies a therapeutic value for TRPA1 antagonist creams for patients with sunburn pain or thermal injury.

Interestingly, TRPA1 inhibition produces analgesia against modalities that are not mediated by

TRPA1-expressing neurons⁹¹. This behaviour is not unprecedented, and has been observed in other TRP receptors, such as TRPV1. Although mechanosensitive nerves do not express TRPV1, resiniferatoxin desensitizes capsaicin-sensitive afferents, resulting in ameliorated mechanical hyperalgesia (and, paradoxically, cold hyperalgesia) in a murine model of arthritic pain⁹². The molecular underpinnings of this phenomenon are not clear. One possibility is that TRPV1 expression is plastic and nerve fibres that do not express TRPV1 under normal conditions might do so under pathological conditions, such as pain⁹³. Similar considerations may also apply to TRPA1.

The journey of TRPA1 antagonists as pain therapeutics to the clinic was given new impetus by the recent purchase by Eli Lilly of the Hydra Biosciences molecules⁹⁴. As of today, TRPA1 small molecule patents have been filed by Ajinomoto Co., Algomedix Inc, Almirall S.A., Boehringer Ingelheim, EA Pharm Co., Eli Lilly, Galderma, Genentech/Roche, Glenmark, Mandom Corp and Orion Corp⁹⁵.

The 'cold and menthol receptor', TRPM8. According to a new model of sensory coding, there are two distinct neuronal populations involved in warmth perception: one population is excited by warmth, whereas the other is blocked by it¹⁸. This latter population expresses TRPM8 and displays ongoing cool-driven firing¹⁸. Accordingly, *Trpm8*^{-/-} mice are incapable of distinguishing warm from cold, and show markedly attenuated cold allodynia^{96,97}. Moreover, in humans, reduced *TRPM8* gene expression is associated with a reduced risk for migraine, and reduced sensitivity to cold and cold pain³⁹. These observations imply a therapeutic potential for small molecule TRPM8 antagonists in the management of cold-induced pain and migraine⁹⁸.

Potent and selective TRPM8 antagonists with acceptable clinical safety profiles have been discovered⁹⁸, many of which bind competitively to the menthol or icilin binding site in the S1–S4 sensor domain (FIG. 3g). Accordingly, these antagonists demonstrated a clear-cut exposure–efficacy relationship in preclinical models, including icilin-induced wet dog shakes in rats, cold pressor test in rodents, and menthol challenge in guinea pigs; these findings predict target engagement for therapeutic dose in humans⁹⁸.

Interestingly, like TRPV1, TRPM8 displayed a basal activation tone⁹⁹. TRPM8 antagonists evoked a mild hypothermic response, but this was not considered a hurdle to clinical use¹⁰⁰. Some TRPM8 antagonists (such as AMG-333 and PF-05105679)^{100,101}, have already progressed into clinical studies, in which they reduced pain in the cold pressor test. Although PF-05105679 did not cause perceptible hypothermia, some volunteers reported a 'hot feeling' in the perioral area that was deemed to be non-tolerable by two study subjects¹⁰⁰. AMG-333 also caused a few grade 1 adverse effects related to TRPM8 antagonism¹⁰¹.

Although most of the attention was focused on antagonists, TRPM8 agonists (such as WS-12 and di-isopropyl-phosphinoyl-alkane, DIPA) also have an analgesic potential. For instance, DIPA was shown to

Cold allodynia

Paradoxical burning sensation when exposed to a cold surface.

Complex regional pain syndrome type I

Also known as reflex sympathetic dystrophy, this syndrome presents as continuous pain and sudomotor activity that is disproportionate to the initiating event.

Wet dog shakes

Rapid and alternating head rotation in rats, an animal model used to quantify central 5-HT_{2A} activity.

Cold pressor test

Assessment of autonomic nervous system function, pain threshold and pain tolerance.

Olmsted disease

Also known as mutilating palmoplantar keratoderma with periorificial keratotic plaques, this is a rare congenital disorder caused by abnormal growth of the skin; it is associated with itching, pain, skin fissures and skin cancers.

Erythromelalgia

Also known as Mitchell disease, this is intense, burning pain (algia) associated with redness (erythro) that primarily affects the feet (mel).

Painful plantar keratoderma

Painful, symmetric callus formation on the pressure points of the soles.

reduce spontaneous painful contractions in the human distal colon¹⁰².

Fading and emerging TRP targets for pain relief. The classical pain targets of TRPV1, TRPA1 and TRPM8 are all expressed in nociceptors^{25,40}. The expression pattern of novel TRP targets for pain relief is more diverse, ranging from sensory neurons (TRPM3) through brain nuclei involved in pain processing (TRPC4 and TRPC5) to the epithelium (TRPV3 and TRPV4) and immune cells (TRPM2).

Gain-of-function mutations in *TRPV3* were discovered in patients with Olmsted disease^{103,104}, erythromelalgia¹⁰⁴, and painful plantar keratoderma¹⁰⁵. As with TRPA1 above, many of these *TRPV3* gain-of-function mutations are at the elbow connecting the S4–S5 linker and the S5 helix (FIG. 3b). Interest in TRPV3 as an analgesic target was first raised by the observation that tissue damage upregulates TRPV3 expression in human sensory ganglia or skin¹⁰⁶. Several companies developed potent and selective TRPV3 antagonists¹⁰⁷. In 2014, the Sanofi-Aventis/Glenmark compound GRC15300 failed a phase II trial in patients with peripheral neuropathy, and the programme was terminated.

Genetic deletion or knockdown of *Trpv4* in mice leads to attenuated pain behaviour in various preclinical models. According to these studies, TRPV4 may play a pivotal part in visceral pain¹⁰⁸. An interesting approach is to use TRPA1/TRPV4 dual inhibitors for chemotherapy-associated neuropathic pain¹⁰⁹.

The molecular mechanisms that underlie the transition from acute to chronic neuropathic pain are largely unknown, hampering drug development. In this transition, TRPV1, TRPA1 and TRPM2 are emerging as important players^{110,111}. For instance, acute pancreatitis has a large component of neurogenic inflammation that can be attenuated by TRPV1 and TRPA1 antagonists^{112,113}. These antagonists also prevented the spouting of pancreatic sensory nerve fibres during the acute pancreatitis attacks, and thereby averted the development of chronic neuropathic pain. As for TRPM2, it is highly expressed in immune cells — including macrophages and microglia — that contribute to inflammatory and neuropathic pain¹¹⁴. In a murine model of neuropathic pain, *Trpm2* knockdown prevented the development of pain-related behaviour following chronic constriction injury¹¹⁴.

TRPM3 has a central role in noxious heat sensing¹¹⁵, making the ‘triad of TRPV1/TRPA1/TRPM3’ a potential multireceptor pain target¹¹⁶. The TRPM3 agonist CIM0216 induced heat hypersensitivity in wild-type mice but not in *Trpm3*^{-/-} mice¹¹⁷. Conversely, TRPM3 antagonists reduced pain responses in several protocols in preclinical studies^{118–120}; again, these results were validated in *Trpm3*^{-/-} animals¹¹⁷.

TRPC4 and TRPC5 are non-selective cation channels that can form homomers and heteromers and are expressed mostly in the amygdala and hippocampus (FIG. 4), but also in peripheral sensory neurons both in rodents¹²¹ and humans¹²². Studies on *Trpc4*^{-/-} rats showed tolerance to visceral pain responses, whereas somatic pain responses were unaffected¹²³.

Furthermore, the non-selective TRPC4/TRPC5 antagonist 4-methyl-2-(1-piperidinyl)quinoline (ML-204) inhibited visceral pain responses in wild-type rats¹²⁴, confirming the role of TRPC4 in visceral pain. Local application of ML-204 to amygdala attenuated neuropathic pain behaviour in rats with spared nerve injury¹²⁴. Genetic inactivation (*Trpc5*^{-/-} mice) or pharmacological blockade of TRPC5 by the small molecule antagonist AC1903 prevented the development of mechanical hypersensitivity and persistent spontaneous or tactile pain in a wide range of murine pain models, including that induced by skin incision, chemotherapy and complete Freund adjuvant injection¹²². We note that these pain conditions are associated with elevated lysophosphatidylcholine (LPC) levels, and exogenous LPS triggers TRPC5-dependent pain behaviour in naive mice¹²²; LPS also causes intensive itching during cholestasis both in rodents and nonhuman primates by activating TRPV4 in skin keratinocytes¹²⁵. Because TRPC5 also regulates prolactin release¹²⁶, TRPC5 antagonists may have enhanced analgesic efficacy in females given that prolactin promotes pain only in that sex. These findings suggest that centrally acting TRPC4 and TRPC5 antagonists could relieve visceral and neuropathic pain, or at least make it more tolerable¹²⁷.

Respiratory disease

TRP channels are attractive targets for the treatment of respiratory diseases¹²⁸ given their widespread expression in the lung, both in immune and structural cells, and their central role in evoking respiratory symptoms like bronchospasm and cough.

TRPV1 in respiratory disease. Inhaled capsaicin evokes coughing in both guinea pigs and humans by activating TRPV1 on C-fibre afferents¹²⁹. Indeed, capsaicin-containing sprays and gas canisters are used by individuals for personal protection and by law enforcement for crowd control¹⁶. Increased cough reflex sensitivity to inhaled capsaicin has been observed in patients with asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and chronic idiopathic cough. These findings suggested that TRPV1 is a credible target to treat both chronic idiopathic cough and cough from inflammatory lung disease¹³⁰. The increased TRPV1 activity may be explained by elevated levels of inflammatory mediators (such as prostaglandin E₂, neurotrophins and bradykinin) in the airways of patients with asthma and with COPD. These endogenous substances activate airway sensory nerves, causing coughing¹³¹. Moreover, neurons undergo phenotypical changes in respiratory diseases both in experimental animals and human challenge models. For instance, in guinea pigs and rats challenged with ovalbumin, or in guinea pigs treated with neurotrophins, the number of TRPV1-positive neurons (particularly of the nodose-originating Aδ subtype) increases, suggesting that changes in neural pathways influenced by their local environment may result in exaggerated functional responses^{132,133}. Moreover, *TRPV1* single nucleotide polymorphisms (SNPs) have been associated with coughing, suggesting that *TRPV1* variants may

enhance susceptibility to coughing in smokers and in subjects with a history of workplace exposure¹³⁴.

Clinical studies tested the postulated causal role of TRPV1 in patients with chronic idiopathic cough and in chronic cough associated with COPD in patient groups with increased cough sensitivity to capsaicin. In patients with chronic idiopathic cough, the TRPV1 antagonist SB-705498 caused a small but statistically significant inhibition of capsaicin-evoked coughing, but no effect on spontaneous coughing frequency¹³⁵. In subsequent studies, XEN-D0501 (a TRPV1 antagonist with superior efficacy and potency) did not improve spontaneous cough frequency in patients with refractory coughing¹³⁶, nor did it affect spontaneous coughing in patients with COPD¹³⁷, which effectively rules out TRPV1 as a relevant therapeutic target for chronic cough in these patient groups, but not in other respiratory diseases associated with exaggerated coughing.

There is widespread non-neuronal TRPV1 expression in the lung, in both structural (such as fibroblast) and immune cells (such as alveolar macrophages)¹³⁸. For example, TRPV1 was detected in human bronchial epithelial cells, with increased expression in patients with refractory asthma¹³⁹. In bronchial epithelium, TRPV1 activation mediates mucin secretion induced by acid and particulates¹⁴⁰, as well as the release of cytokines¹⁴¹ and ATP¹⁴². In a preclinical model of cigarette smoke exposure used to mimic the inflammatory response seen in COPD, the TRPV1 inhibitor JNJ17203212 reduced cigarette smoke-induced ATP release from human bronchial epithelial cells¹⁴². Furthermore, bronchiolar lavage fluid collected from *Trpv1*^{-/-} mice following cigarette smoke exposure had diminished ATP release and neutrophilia compared with that of wild-type mice¹⁴². Conversely, whole-lung homogenates from patients with COPD showed increased *TRPV1* mRNA expression compared with samples from smokers without COPD and healthy non-smokers, suggesting an association between TRPV1 expression and disease pathophysiology¹⁴².

The role of TRPV1 in asthma is controversial; some studies show no impact whereas others show protection through TRPV1 inhibition by antagonists or genetic inactivation. For instance, in rodent ovalbumin challenge models, TRPV1 blockade improved standard end points, including eosinophilia, airway hyperresponsiveness and the late asthmatic response¹⁴³. Furthermore, TRPV1 inhibition reduced the interleukin (IL)-13-driven asthma phenotype in mice, and blocked airway hyperresponsiveness to histamine in guinea pigs following ovalbumin exposure¹⁴⁴. Similarly, data from a murine house-dust mite model suggested that TRPV1, but not TRPA1, inhibition reduced airway cellular inflammation and airway hyperresponsiveness¹⁴³. Although many of the effects seen in this study were not statistically significant, there was a consistent suppression across the functional end points measured, suggesting a role for TRPV1 in CD4⁺-dependent allergic asthma models.

In summary, the reasons for the observed differences in studies investigating a role for TRPV1 in allergic asthma are unclear, but could be due to differences in species, strains, antigens and interventions used to dissect TRPV1 biology.

TRPA1 antagonists. TRPV1 and TRPA1 are often co-expressed in sensory neurons that innervate the airways, but they are also found separately^{128,138,145}. TRPA1 agonists (like cinnamaldehyde) evoke human vagus nerve depolarization and induce coughing in both guinea pigs and human volunteers¹⁴⁶. Conversely, TRPA1 antagonists (such as GRC-17536 and HC-030031) are potential anti-tussive agents^{147,148}. In the lung, TRPA1 is also expressed in bronchial epithelial cells and fibroblasts¹⁴⁹.

TRPA1 is an interesting respiratory target because it is activated by known lung irritants including natural products, such as allyl isothiocyanate, allicin and cannabidiol¹⁵⁰, found in mustard oil, garlic and cannabis, and by environmental irritants, such as acrolein¹⁵¹, that are present in air pollution and cigarette smoke¹⁵². These electrophilic agonists covalently attach to a hypersensitive cysteine in the cytoplasmic domain of TRPA1 (REF.⁸²) (FIG. 3c). TRPA1 is also activated by reactive and electrophilic by-products of oxidative stress (such as ROS), and electrophiles like hypochlorite and hydrogen peroxide^{81,153}. Diesel exhaust particles can also activate airway C-fibre afferents via TRPA1 (REF.¹⁵⁴). These particles contain polycyclic aromatic hydrocarbons that stimulate mitochondrial ROS production by interacting at the aryl hydrocarbon receptor. This observation links diesel exposure to respiratory symptoms¹⁵⁴.

In addition to environmental irritants, TRPA1 is also activated indirectly by inflammatory mediators¹⁵¹ (such as bradykinin, PGE₂ and prostaglandin D₂), which are elevated in the bronchoalveolar lavage fluid of patients with asthma and COPD¹⁵⁵. We note that the exhaled breath of patients with inflammatory airway disease is more acidic than that of healthy volunteers¹⁵⁶. This is interesting because inhalation of low pH solutions, such as citric acid, causes coughing in both guinea pigs and humans. In fact, inhaled citric acid is used in the clinic to evaluate cough reflex sensitivity. Citric acid was thought to evoke cough by virtue of its low pH and subsequent activation of TRPV1 and acid-sensing ion channels (ASIC)^{157,158}. However, TRPA1 antagonists (such as GRC-17536) also inhibited citric acid-induced coughing in conscious guinea pig models¹⁴⁷. It is not yet known whether the low pH component of citric acid or the resulting increased osmolarity is responsible for activating TRPA1 (or TRPV1) to evoke coughing.

TRPA1 has been implicated in the pathophysiology of allergic asthma^{159,160}. In allergic individuals, exposure to relevant antigens can lead to an early asthmatic response followed, in certain patients, by a corticosteroid-sensitive, late asthmatic response. Despite its widespread use in the clinical assessment of new therapeutic entities, the mechanisms underlying late asthmatic response remain unclear. Following allergen challenge, activation of TRPA1 stimulates vagal broncho-pulmonary C-fibres and this induces late asthmatic response in the Brown Norway rat asthma model¹⁵⁹. The mechanism of action is unclear, but the allergen probably stimulates the channel indirectly via the release of endogenous TRPA1 activators, possibly mast cell products like tryptase.

TRPA1 may also have a key role in the airway hyperresponsiveness characteristic of asthma. Indeed, the

TRPA1 antagonist, HC-030031, reverses airway hyper-responsiveness induced by acetylcholine in an ovalbumin mouse model¹⁵⁹. Toluene di-isocyanate (TDI), a reactive compound used in the manufacture of polymeric derivatives and known to activate TRPA1 (REF.¹⁶¹), can also evoke respiratory symptoms, including late asthmatic response, in exposed workers¹⁶². Non-allergic airway hyperresponsiveness can be induced by a single exposure of hypochlorite (a known TRPA1 agonist) in ovalbumin-exposed wild-type mice but not in *Trpa1*^{-/-} mice¹⁶³. Ovalbumin-challenged wild-type rats showed signs of airway inflammation⁸⁶, whereas *Trpa1*^{-/-} rats did not, which again suggests that TRPA1 inhibition has therapeutic potential for asthma.

Lower respiratory tract infections are a leading cause of death in adults and pneumonia is the single largest cause of death in children¹⁶⁴. Coughing is the main method of spreading bacteria from a human host into the environment. However, the mechanisms of coughing in patients with lower respiratory tract infections are unknown. We note that lipopolysaccharide, which is found in the outer membrane of Gram-negative bacteria, has been identified as a TRPA1 activator that exerts fast excitatory actions via TRPA1 independent of Toll-like receptor-4 (TLR4) activation¹⁶⁵. This finding implicates TRPA1 as a driver of respiratory symptoms following bacterial infections and warrants further investigation.

Although associations have been found between *TRPA1* SNPs and susceptibility to airway disease¹⁶⁶, the evidence linking TRPA1 dysfunction to respiratory disease pathophysiology is still rudimentary. Drug discovery efforts have been hampered by the limited bioavailability of TRPA1 antagonists^{167,168}. Recently,

a potent, selective and orally bioavailable small molecule TRPA1 antagonist, GDC-0334, with good target engagement in human volunteers, has been reported¹⁶⁹. In preclinical models of respiratory disease, GDC-0334 inhibited cough response, airway smooth muscle hyper-reactivity and oedema formation in several species¹⁶⁹. It is hoped that clinical studies with GDC-0332 (or other compounds with good bioavailability) will answer the question of whether blocking TRPA1 in respiratory disorders has therapeutic promise¹⁶⁸.

TRPV4 antagonists. TRPV4 is expressed in a wide range of non-neuronal cell types in human airways, including airway and vascular smooth muscle, epithelial cells, fibroblasts and inflammatory cells (such as macrophages and neutrophils)⁴. Multiple endogenous pro-inflammatory and environmental stimuli act in concert to activate TRPV4 (REF.⁴). Accordingly, TRPV4 activation is implicated in the pathophysiology of chronic lung diseases^{170–172}.

TRPV4 was referred to as ‘the gatekeeper of pulmonary capillary permeability’. Its contribution to respiratory disease is probably best understood in the development of acute lung injury¹⁷³. TRPV4 is involved in disrupting the epithelial and endothelial barrier function¹⁷³, which suggests an important role in lung oedema formation associated with inflammation and tissue injury¹⁷⁴. In the rodent lung, TRPV4 blockade, or knockdown, inhibited ventilator- and acid-induced lung injury, by significantly reducing the infiltration of inflammatory cells (including neutrophils and macrophages) and lung injury scores^{175,176}. These data suggest a broad-spectrum inhibition of acute lung injury regardless of causality. Indeed, TRPV4 inhibitors are developed by the National Institute of Health (NIH) as countermeasures against chemical threats¹⁷⁷.

High pulmonary venous pressure is a major cause of heart failure. TRPV4 antagonists inhibit pulmonary oedema associated with heart failure in animal models¹⁷⁸, paving the way towards clinical trials. On the basis of these observations, calls have been made to evaluate the effect of TRPV4 inhibitors in COVID-19 patients at risk of lung oedema¹⁷⁹ (BOX 2).

TRPV4 is also implicated in chronic respiratory diseases such as asthma, COPD and chronic refractory cough^{170–172}. Its role in diverse pathologies across respiratory disease has been explained by TRPV4-induced ATP release in a pannexin 1-dependent manner with resultant activation of purinoceptors^{180,181}. Consistent with this hypothesis, TRPV4-induced ATP release was demonstrated in human airway epithelial cells^{142,182} and smooth muscle cells¹⁸¹. TRPV4 and purinoreceptor P2X3 antagonists were shown to inhibit A δ sensory afferent nerve fibre activation and coughing induced by TRPV4 agonists or hypo-osmolar solutions (known to activate TRPV4)¹⁸³. This study identified the TRPV4–ATP–P2X3 axis as a driver of airway sensory nerve reflexes such as coughing, and clinical trials with P2X3 receptor antagonists, such as AF-219, would support the role of ATP as a driver of the cough reflex¹⁸³.

In the context of asthma, TRPV4 agonists can induce a mast cell-dependent, contractile response in human

Box 2 | Potential indications for TRP channel ligands: COVID-19 and cognitive decline in diabetes

SARS-CoV-2 may cause potentially fatal acute respiratory syndrome (ARDS) and pulmonary oedema in a subset of patients with COVID-19. As several TRPV4 antagonists that have already been proved safe in clinical trials can protect the alveolo-capillary barrier, these compounds could be protective in patients with COVID-19 at risk of lung oedema¹⁷⁹. The afferent TRPV1-expressing pulmonary innervation has also been implicated in ARDS; drugs that silence these fibres (for example, resiniferatoxin) can also improve clinical outcome²⁹⁷. Deadly viruses can exploit the endo-lysosomal trafficking system of the host cells for penetration and replication. The integrity of this system depends on mucolipins (TRPMLs). Therefore, compounds that interfere with endo-lysosomal maturation and trafficking via TRPMLs may prevent the virus from entering the host cells²⁹⁸.

In the brain, blood flow must meet the dynamically changing metabolic demands of active neuronal populations. The machinery of neuro-vascular coupling (NVC) senses the change in neuronal activity and redirects the blood flow accordingly. Most recently, TRPA1 expressed in capillary endothelium has emerged as a key player in this functional hyperaemic response²⁹⁹. In response to neuronal activity, TRPA1 initiates a rapid Ca²⁺ signal, which is dependent on the endothelial pannexin-1 channel and purinergic P2X receptors²⁹⁹. This current is subsequently converted into an inward rectifying K⁺-mediated electric signal that guides blood flow by regulating the tone of the arteriole wall. Disturbed NVC is thought to be a major risk factor for cognitive impairment in diabetic patients³⁰⁰. In diabetes, methylglyoxal (and probably also other harmful by-products of glycolysis) bind to and activate TRPA1 (REF.⁷⁹). Therefore, one can speculate that pathogenic metabolic products may impair NVC in diabetic patients in a capillary endothelial TRPA1-dependent fashion. If so, TRPA1 antagonists could prevent cognitive decline by protecting the NVC in patients with diabetes in addition to protecting nerve fibres⁸⁸ and relieving pain during diabetic polyneuropathy⁸⁷. This would be an important added benefit of TRPA1 antagonist therapy.

SMAD

Downstream signal transducer for the receptors of the transforming growth factor β (TGF β) superfamily.

Neurogenic bladder

Urinary condition caused by impaired neuronal control (for example, by spinal cord injury or multiple sclerosis) of bladder function.

Interstitial cystitis

Poorly understood clinical condition that predominantly affects young women and causes recurrent pain in the pelvic region associated with problems with urination.

Akita mice

Genetic mouse model of type 1 diabetes.

bronchial and guinea pig tracheal airway smooth muscle *in vitro*. This effect is attributed to TRPV4-induced ATP release from airway smooth muscle¹⁸¹, which activates P2X4 receptors on mast cells to release cysteinyl leukotrienes (Cys LT); this, in turn, activates the Cys LT-1 receptor to evoke contraction¹⁸⁴.

COPD is an inflammatory lung disease associated with cigarette smoking. Smoke exposure was reported to cause a dose-dependent increase in ATP release — which may drive the airway inflammation — from primary human bronchial epithelial cells, and this effect was attenuated by blockers of TRPV1, TRPV4 and pannexin-1 channels¹⁴². Interestingly, lung tissue from patients with COPD shows an increase in *TRPV4* mRNA expression compared with healthy smokers and non-smokers¹⁴².

Genetic variants of *TRPV4* have been associated with asthma¹⁸⁵ and COPD¹⁸⁶. For example, the loss-of-function variant, TRPV4-P19S, was linked to childhood asthma¹⁸⁵, and a genome-wide association study highlighted seven *TRPV4* SNPs that conferred increased susceptibility to COPD¹⁸⁶. It was postulated that TRPV4 modulators could influence COPD pathophysiology, but this hypothesis has yet to be tested.

TRPV4 activity is upregulated in lung fibroblasts derived from patients with IPF¹⁸⁷. In IPF models, *Trpv4*^{-/-} mice are protected from fibrosis¹⁸⁷. TRPV4 modulates transforming growth factor (TGF)- β 1-dependent actions in a SMAD-independent manner with enhanced actomyosin remodelling and increased nuclear translocation of the α -smooth muscle actin-transcription co-activator, myocardin-related transcription factor (MRTF)-A^{188,189}. These data point to TRPV4 inhibition as a potential therapeutic approach in pulmonary fibrosis¹⁸⁹. Interestingly, like asthma and COPD, increased amounts of ATP have been detected in the airways of patients with IPF¹⁹⁰, but currently there is no evidence linking the TRPV4/pannexin/ATP axis to IPF.

TRPM8. TRPM8 is a cold-responsive receptor^{7,8} that, in principle, may mediate coughing and bronchoconstriction caused by inhalation of cold air. The role of TRPM8 activation in cough is, however, controversial because menthol, a TRPM8 agonist, paradoxically inhibits citric acid-induced cough in both guinea pigs¹⁹¹ and humans¹⁹², and causes a temporary decrease in capsaicin-evoked cough in healthy individuals¹⁹³. Indeed, menthol inhibits sensory nerve activation and is used as an over-the-counter antitussive medication. Menthol was — and in many countries still is — often added to cigarettes to inhibit irritancy in the airways, which may promote nicotine addiction. Therefore, menthol is now banned from cigarettes in the USA.

There is still a big question mark over whether the beneficial effects of menthol in the lung are mediated via activation of TRPM8. This is likely to be confounded by the lack of selective tools. For example, in addition to their effects on TRPM8, both menthol and icilin activate and then block TRPA1 (REF.¹⁹⁴) (FIG. 3c,d,g). Several recently developed TRPM8 inhibitors should help to elucidate the role of this channel in respiratory disease biology and pathophysiology.

The genito-urinary system

In the neurogenic bladder, the TRPV1-expressing C fibre-driven micturition reflex, which is inactive under physiological conditions, resumes control of the bladder functions¹⁶. Intravesical administration of a large enough dose of TRPV1 agonist (capsaicin¹⁹⁵ or resiniferatoxin¹⁹⁶) to desensitize the C-fibres provides lasting relief in patients with neurogenic bladder by increasing bladder capacity and reducing the number of incontinent episodes¹⁹⁷. Furthermore, in bladder biopsy samples taken from patients with interstitial cystitis, the density of TRPV1-expressing fibres correlated with clinical symptoms¹⁹⁸. Yet, in a phase II clinical trial intravesical resiniferatoxin failed to meet the primary end point (symptom improvement according to the Global Response Assessment, a 7-point scale rating overall change in symptoms), faring no better than placebo after 4 weeks¹⁹⁹. Therefore, it is likely that the increased TRPV1 expression in the bladder biopsy samples was not the cause but a consequence of the disease. Parenthetically, an interesting (and controversial) indication of topical resiniferatoxin desensitization is its application to the penis to prevent premature ejaculation²⁰⁰.

Animal experiments suggested a therapeutic value for TRPV1 (GRC-6211)²⁰¹ and TRPM8 (RQ-00434739 (REF.²⁰²) and KRP-2529 (REF.²⁰³)) antagonists for suppressing hyperactivity in the chronically inflamed bladder, which is yet to be tested in the clinic.

In the bladder, TRPV4 is expressed both in urothelium and in the detrusor muscle, where its activation causes sustained muscle contractions²⁰⁴. This is consistent with the spotty incontinence phenotype of the *Trpv4*^{-/-} mice²⁰⁵. By contrast, the TRPV4 agonist GSK1016790A evokes bladder contractions²⁰⁶. Of relevance, TRPV4 expression is increased in human overactive bladder mucosa²⁰⁷. These and other preclinical findings imply that a TRPV4 agonist may improve the underactive bladder²⁰⁸, whereas an antagonist could be valuable in managing the overactive bladder²⁰⁹.

The TRPC5 antagonist AC-1903 prevented podocyte loss in a rodent model of focal segmental glomerulosclerosis, suggesting a novel interaction for renal allograft protection²¹⁰. TRPC6 is highly expressed in the kidney, but the role of TRPC6 in renal pathology is complex, which has hindered drug development. For example, BI-749327, a selective TRPC6 antagonist, ameliorates renal fibrosis and dysfunction²¹¹, whereas deletion of *Trpc6* worsens glomerular injury in Akita mice²¹². Accordingly, a loss-of-function *TRPC6* variant (G757D) is associated with focal segmental glomerulosclerosis²¹³. These latter observations warrant caution when using TRPC6 blockers in humans.

Dermatology and ophthalmology

In the skin and the eye, TRPs are attractive pharmacological targets because they are amenable to topical therapy, probably reducing the risk of serious adverse effects. TRP channels are broadly expressed in various skin cell types (including keratinocytes, melanocytes, skin appendage cells, nerve endings and immune cells), with functions ranging from skin barrier function and hair growth

through wound healing to cutaneous inflammation and itching^{19,78,214}.

TRPA1, TRPV3, TRPV4 and, to a lesser degree, TRPV1 and TRPM8 are all promising targets to relieve itching¹⁹. TRPA1 expression is elevated in human psoriatic skin biopsies²¹⁵. Accordingly, *Trpa1*^{-/-} mice show reduced scratching behaviour in a murine model of chronic itching, and lack the extensive epidermal hyperplasia prevalent in psoriasis and atopic dermatitis²¹⁵. Transgenic mice with skin-targeted, gain-of-function *Trpv3*^{Gly573Ser} (FIG. 3b) exhibit scratching behaviour²¹⁶. In humans, gain-of-function *TRPV3* mutations (G568D and Q580P; FIG. 3b) were described in palmoplantar keratoderma¹⁰⁵, and increased TRPV3 expression was reported in post-burn pruritus²¹⁷. Similarly, TRPV4 is overexpressed in skin biopsy samples from patients with chronic pruritus²¹⁸, and genetic deletion of *Trpv4* ameliorates itching in mouse models of chronic itch²¹⁹. A TRPM8 agonist (menthoxypropanediol) cream was also reported to relieve human itching²²⁰.

The TRPV1 antagonist PAC-14028 (now in phase III clinical trials) improves skin barrier function and relieves pruritus in patients with atopic dermatitis²²¹. Although topical TRPV1 antagonists are generally regarded as harmless, a recent study suggests caution. In TRPV1-Ai32 optogenetic mice, cutaneous light stimulation activated TRPV1-expressing neurons with resultant local-type 17 immune response²²², in which a cascade of cytokine-mediated events leads to activation of antimicrobial responses in keratinocytes and recruitment of neutrophils to the skin. If this observation holds true in humans, patients treated with topical TRPV1 antagonists may be susceptible to cutaneous fungal and bacterial infections.

TRPA1 is also involved in ultraviolet radiation-induced burn. In mice, topical administration of the TRPA1 antagonist, HC-030031, applied after irradiation blocked the development of mechanical and thermal allodynia²²³.

TRPV1 and TRPV3 have been implicated in hair growth. For example, *Trpv3* null mice have a thick, wavy coat of hair²²⁴ whereas mice with constitutively active *Trpv3* (the DS-*Nh* strain) are hairless²²⁵. Indeed, TRPV3 activation has been shown to inhibit human hair growth²²⁶. Accordingly, topical TRPV3 agonists and antagonists may be beneficial in patients with hirsutism and alopecia, respectively. Nude DS-*Nh* animals also develop a skin condition similar to human atopic dermatitis²²⁷. Furthermore, TRPV3 activation blocks lipogenesis in human sebocytes²²⁸, suggesting a therapeutic potential for a TRPV3 antagonist in dry skin dermatoses.

TRPV1 has been implicated in psoriasis²²⁹ and TRPV4 was named as a potential target in rosacea²³⁰. Recently, gain-of-function *TRPM4* mutations (I1033M and I1040T; FIG. 3d) were linked to erythrokeratoderma²³¹. Even if their connection to TRP channels is still weak, all these diseases represent unmet medical needs.

Eye drops containing a TRPM8 agonist help to moisturize the cornea in patients with dry eye disease²³². In animal experiments, the TRPV4 antagonist, HC-067047, protected against the fibrosis (stromal opacification) that develops following alkali burn injury²³³. Last, intraocular

TRPV1 antagonist administration has been proposed to relieve allergic conjunctivitis²³⁴.

Central nervous system

TRPA1 as a therapeutic target in stroke and in multiple sclerosis. Although *Trpa1*^{-/-} mice lack any obvious neurological phenotype and there is little, if any, detectable mRNA signal in the central nervous system²³⁵, functional TRPA1 seems to be present, albeit at low levels, in the brain: in glial cells (astrocytes and oligodendrocytes)²³⁶, in cortical neurons²³⁷, in cerebral endothelium²³⁸ and in Schwann cells²³⁹. This discrepancy between positive function-based TRPA1 results and weak or missing *Trpa1* mRNA signals is puzzling and yet to be explained.

The potential therapeutic use of brain-permeable TRPA1 antagonists for neuroprotection has emerged from an elegant electrophysiological study²⁴⁰. White matter is particularly vulnerable to hypoxia associated with stroke. Glutamate release and subsequent activation of N-methyl-D-aspartate (NMDA) receptors in oligodendrocytes is thought to underlie hypoxia-induced white matter injury²⁴⁰. Pharmacological or genetic inactivation of TRPA1 prevented hypoxia from damaging and ultimately killing oligodendrocytes after stroke²⁴⁰. On a related note, TRPV1-mediated hypothermia reduced stroke volume by 50% and promoted functional recovery after ischaemic stroke in mice³⁰.

Oligodendrocytes are also affected in multiple sclerosis. Cuprizone-induced demyelination is widely used as a multiple sclerosis model to assess the potential therapeutic efficacy of novel multiple sclerosis treatments. In this model, pharmacological blockade or genetic deletion of *TRPA1* reduced oligodendrocyte apoptosis²⁴¹. Furthermore, methylglyoxal, a known TRPA1 activator⁷⁹, accumulated in the white matter lesions of multiple sclerosis²⁴². Dimethyl fumarate, used to treat multiple sclerosis and psoriasis, and known to activate the antioxidant response through Nuclear factor erythroid 2-related factor 2 (NRF2), was found to activate TRPA1 in immune cells independent of NRF2 (REF. 243). This novel NRF2-independent mechanism may contribute to the peripherally restricted immunosuppressive action of dimethyl fumarate.

TRPA1 in anxiety, dementia and seizures. *Trpa1*^{-/-} mice show reduced anxiety-like behaviour, and this beneficial effect can be reproduced with TRPA1 antagonists in healthy, wild-type mice²⁴⁴. The neural circuit responsible for the antidepressant action of TRPA1 antagonism is currently unknown. Importantly, ageing *Trpa1*^{-/-} mice also exhibited improved memory (fewer reference memory errors), implying a role for TRPA1 in age-related memory decline²⁴⁵. Together, these findings identify TRPA1 as a potential target in the pharmacotherapy of anxiety and dementia, a common combination in the elderly (for TRPA1 in capillary endothelium in the brain, and memory decline in diabetic patients, see BOX 2).

However, *Trpa1*^{-/-} mice also show defects in white matter myelination, with the myelin basic protein level downregulated and the number of mature oligodendrocytes reduced²⁴⁶. According to this observation, TRPA1 may play a critical part in the maturation process of

Optogenetic mice

Genetically modified mice expressing light-sensitive ion channels in neurons; light is used to control neuronal function in vivo.

Psoriasis

Disease of the skin that causes red, flaky, crusty plaques.

Rosacea

A common skin condition that causes redness and visible blood vessels in the face; it may also affect the nose (rhinophyma) and the eyes (dry, irritated, swollen eyes).

Erythrokeratoderma

A group of keratinization disorders that manifest in erythema (redness) and hyperkeratosis (scaling); most cases are indolent with no effect on general health.

Multiple sclerosis

A neurological disease in which inflammation is thought to drive disease progress.

Box 3 | Phenome-wide association studies to support TRP channel target validation

The complex role of TRP channels in various physiological functions poses the question of whether the risk–benefit ratio of a given TRP channel is attractive enough to start a drug discovery programme that may deliver novel drug candidates after only 5–10 years of hard work. Another issue related to drug target validation is how well efficacy and safety findings in animal models translate to human studies. It is generally accepted that incorporating human-relevant data at early stages of the drug discovery process increases the likelihood of success. A recent exciting development to accelerate drug target validation is to use large-scale, real-world patient cohorts from biobanks and other resources to associate phenotypes with genotypes in an unbiased manner³⁰¹. Indeed, there is evidence that targets with genetic support are approximately twice as likely to lead to an approved drug compared with those without such support. A genetic variant of a given protein may be associated with a particular disease-relevant phenotype without obvious safety implications or, vice versa, a variant may be implicated in a given disease along with several additional unwanted phenotypes. The recent availability of genetic epidemiological tools such as phenome-wide association studies³⁰¹ and Mendelian randomization, as well as large-scale real-world clinical datasets, allows for the reliable prediction of in vivo consequences of the modulation of a given target directly in humans. Efficacy and safety signals derived from such ‘virtual’ trials are increasingly likely to drive the benefit–risk discussions for individual TRP channels.

oligodendrocytes, because the myelination process is likely to continue throughout life during new skill learning, and therefore chronic and complete block of TRPA1 in oligodendrocytes may interfere with myelination. However, robust therapeutic efficacy can probably be achieved during intermittent partial pharmacological block of TRPA1 in humans, allowing preservation of the physiological house-keeping function of TRPA1.

TRPA1 in astrocytes may constitutively regulate excitatory neurotransmission in healthy brain²³⁷. If confirmed, central TRPA1 inhibition may interfere with memory formation, contradicting the memory phenotype observed in *Trpa1*^{-/-} mice²⁴⁵. By contrast, a phase I study of a centrally acting TRPA1 antagonist in healthy volunteers revealed no central nervous system toxicity issues at concentrations that were several-fold above the IC₅₀ value²⁴⁷. One potential explanation for this discrepancy is that constitutive TRPA1 activation in brain slice astrocytes is an experimental artefact: large amounts of reactive lipid hydroperoxides and other putative TRPA1 agonists may be leaking from damaged and dead cells.

Hippocampal slices from an Alzheimer disease (AD) mouse model provided compelling evidence that TRPA1 activation by β amyloid contributes to network hyperexcitability, possibly driving silent seizures²⁴⁸. This is important because antiepileptic drug use in AD is associated with increased risk for stroke²⁴⁹. Central TRPA1 antagonism may provide a safe therapy for seizures in AD.

Parentetically, in the triple-transgenic AD mouse model (3xTg-AD^{+/+}), *Trpv1*^{-/-} animals had better memory function and lower tau accumulation in the hippocampus compared with *Trpv1* wild-type mice²⁵⁰. The challenge, of course, is to deliver TRPA1 and/or TRPV1 antagonists to the central nervous system without causing unacceptable systemic side effects.

TRPM2, TRPM3 and TRPM4: from stroke to bipolar disorder. TRPM2 is a well established redox sensor²⁵¹ and a potential target in hypoxic-ischaemic brain injury²⁵². TRPM2 is implicated in neuronal death by ROS^{251,252}.

Indeed, the TRPM2 antagonist JNJ-28583113 protects cells from oxidative stress-induced death²⁵³. In a mouse model of cardiac arrest and cardiopulmonary resuscitation, TRPM2 inhibition improved functional recovery following cerebral ischaemia²⁵⁴. In the hippocampus of patients with major depressive disorder, increased *TRPM2* mRNA levels were detected, suggesting TRPM2 as a target for treating depression²⁵⁵. *TRPM2* is also a susceptibility gene for bipolar disorder²⁵⁶. *Trpm2*^{-/-} mice display impaired social cognition, and a subset of bipolar patients possess the hypoactive D543E *TRPM2* gene variant²⁵⁶ (FIG. 3d). The connection between TRPM2 and bipolar disorder was further strengthened by the finding that TRPM2 regulates the phosphorylation of glycogen synthase kinase-3 (GSK3), the main target of lithium²⁵⁷.

In the central nervous system, TRPM3 is expressed in both glia and neurons. The discovery that primidone — a drug that has long been approved for the treatment of epilepsy and essential tremor — blocks TRPM3 at concentrations that are achieved in the brain during pharmacotherapy validates TRPM3 as a promising neurological drug target²⁵⁸. One may argue that excessive TRPM3 activation can drive white matter injury and thus a centrally acting TRPM3 antagonist may be disease-modifying by protecting white matter. Most recently, gain-of-function *TRPM3* variants (such as V837M; FIG. 3d) have been linked to intellectual disability and epilepsy²⁵⁹, although it is not clear how this observation can be exploited for pharmacotherapy.

TRPM4 is a Ca²⁺-activated non-selective cation channel in vascular smooth muscle that has a key role in myogenic constriction of cerebral arteries²⁶⁰. TRPM4 is closely associated with the sulfonyleurea receptor-1 (SUR1)²⁶¹, which explains the sensitivity of TRPM4 to the antidiabetic compound glibenclamide, a SUR1 inhibitor. In rodent models, spinal cord injury upregulated TRPM4 during secondary haemorrhage, and the increase in haemorrhage was prevented by genetic silencing of *Trpm4* by antisense in rats or in *Trpm4*^{-/-} mice²⁶². In rats, siRNA-mediated silencing of *Trpm4* reduced infarct volume in a permanent stroke model, indicating that TRPM4 inhibition may improve blood–brain barrier integrity after ischaemic stroke reperfusion²⁶³. SUR1-TRPM4 forms a heteromer complex with aquaporin-4, which was shown to amplify ion–water osmotic coupling and thereby drive astrocyte swelling in stroke. These observations motivated investigation of the clinically well tolerated glibenclamide as a SUR1-TRPM4 antagonist in stroke patients²⁶⁴. In a small-scale study, glibenclamide was shown to improve outcome²³⁴. A phase III clinical trial with intravenous glibenclamide (BIIB093) is currently recruiting stroke patients (NCT02864953)²⁶⁵.

TRPM4 was also shown to mediate axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and such effects could be antagonized by glibenclamide, suggesting that TRPM4 inhibition may be a novel target for multiple sclerosis²⁶⁶.

Inhibition of TRPCs has anxiolytic and antidepressant effects. Behavioural studies with *Trpc4*^{-/-} and *Trpc5*^{-/-} mice showed positive results in models that predict

Phenome-wide association study

A study designed to test for associations between a specific genetic variant (such as single nucleotide polymorphism, SNP) and a wide range of phenotypes or disease risks in a large cohort of individuals.

Lithium

Mainstay pharmacotherapy for bipolar disorder for acute mood episodes, switch prophylaxis and suicide prevention.

Lysozomes

Intracellular organelles with a key role in cellular waste handling and recycling.

Mucopolipidosis type 4

An autosomal recessive lysosomal storage disorder causing delayed mental and motor development and vision impairment that worsens with time; patients present with intellectual disability (absent speech), difficulty swallowing and weak muscle tone.

Non-invasive, low-intensity, low-frequency ultrasound (LILFU). A promising transcranial approach to stimulating brain pathways.

anxiolytic and antidepressant action^{267,268}. This effect could be replicated by a small molecule, a TRPC1/TRPC4/TRPC5 pan-inhibitor, HC-070, which implies a therapeutic potential to treat anxiety disorders²⁶⁹. Hydra Biosciences and Boehringer Ingelheim have started a phase I trial with their TRPC4/5 inhibitor²⁷⁰. The *Trpc4*^{-/-} rats also displayed reduced cocaine self-administration without deficits in learning for natural rewards²⁷¹. If this observation is confirmed in humans, a TRPC4 antagonist may prove clinically useful in addiction. TRPC5 has also been implicated in oxidative neuronal death, implying a role in neuroprotection in neurodegenerative diseases like Huntington disease²⁷². The recent availability of potent, selective TRPC5 antagonists like NU-6027 and AC-1903 may help test this hypothesis.

TRPML1 agonists for the treatment of neurodegenerative diseases. TRPML1 is a Ca²⁺-permeable non-selective cation channel expressed in lysosomes²⁷³. Loss-of-function *TRPML1* mutations cause type-IV mucopolipidosis²⁷⁴, a rare genetic disease with predominantly neurological symptoms. Lysosomal Ca²⁺ signalling by TRPML1 regulates autophagy and lysosomal biogenesis²⁷⁵, and TRPML1 levels in lysosomes are controlled by the transcription factor-EB (TFEB)²⁷⁶. The subcellular localization and activity of TFEB is also regulated by phosphorylation mediated by Mammalian Target of Rapamycin (mTOR)²⁷⁵. The dephosphorylated form of TFEB translocates into the nucleus, where it induces the transcription of target genes, including *TRPML1* (REF.²⁷⁵). TFEB has attracted recent attention for its ability to clear pathogenic molecules in mouse models of Parkinson and

Alzheimer disease²⁷⁷. In Parkinson disease mouse models, TRPML1 regulates α-synuclein exocytosis in dopaminergic neurons²⁷⁸. On the basis of these observations, a small molecule TRPML1 agonist could be a disease-modifying agent in neurodegenerative diseases. A recent structure of TRPML1 with the agonist ML-SA1 bound under the pore helix²⁷⁹ — analogous to propofol in TRPA1 or cannabidiol (CBD) in TRPV2 — could aid in developing such agonists (FIG. 3e,f). We note that Merck purchased Calportra, a company developing TRPML1 agonists for US\$576 million in November 2019 (REF.²⁸⁰).

Cancer, obesity and diabetes

Several TRP channels show altered expression in cancers, but it is unclear whether this is cause or consequence of the disease. The use of altered TRP protein expression for cancer diagnosis and prognostication is beyond the scope of this Review. However, such altered TRP channel expression may constitute a therapeutic target. For example, high-grade astrocytoma shows increased TRPV1 expression compared with normal brain²⁸¹. High-dose capsaicin administration can kill neurons owing to the Ca²⁺ overload it causes (FIG. 2), and thus TRPV1 agonists may help to eradicate this brain tumour. Unfortunately, it is unclear how to deliver capsaicin to the brain in doses sufficiently high to kill tumour cells without causing unacceptable side effects. Oesophageal and head-and-neck squamous cell carcinomas also overexpress TRPV1 and TRPA1 (REF.²⁸²). These cancers are more promising targets for TRPV1 and/or TRPA1 agonist therapy inasmuch as they are amenable to topical administration.

TRPV1 gene polymorphism has been linked to eating habits in children²⁸³. There is anecdotal evidence that dietary capsaicin may help maintain a healthy body weight ('exercise in a pill')²⁸⁴. Even if true, it is unclear whether this is an on-target effect of capsaicin on TRPV1, or whether is due to capsaicin-induced changes in the gut microbiota²⁸⁵, as experiments with *Trpv1*^{-/-} mice provided conflicting reports⁷⁸.

TRPM5 is a calcium-activated cation channel activated downstream of taste receptors and other chemosensory receptors. Unlike wild-type mice, which overeat chocolate and become obese, *Trpm5*^{-/-} animals maintain their normal weight when on a carbohydrate-rich diet²⁸⁶. Interestingly, these animals also consume less alcohol²⁸⁷, implying value for a TRPM5 antagonist in obesity and/or alcohol use disorder. By contrast, *Trpm8*^{-/-} mice are obese owing to daytime hyperphagia²⁸⁸, whereas the TRPM8 agonist, icilin, increases energy expenditure, and reduces body weight, in mice²⁸⁹. These observations identify TRPM8 as another potential target in diet-induced obesity.

Type 2 diabetes mellitus (T2DM) has reached pandemic proportions. To date, no disease-modifying treatment is available for T2DM patients. Accumulating evidence suggests that the sensory nervous system is involved in the progression of T2DM by maintaining a low-grade inflammation via TRPV1 (REF.²⁹⁰). Indeed, oral glucose tolerance and glucose-stimulated insulin secretion were improved by both genetic inactivation (*Trpv1*^{-/-} mice) and pharmacological blockade of TRPV1 by the small molecule antagonist BCTC²⁹¹. The TRPV1

Box 4 | Outstanding questions in the TRP field

- Is it possible to achieve further improvement in 'drug-likeness' of TRPA1 antagonists: that is, improved solubility and metabolic stability while maintaining high potency?
- Only a few therapeutic TRP channel selective antibodies have so far been developed. Will more effort be put into developing therapeutic TRP channel antibodies in the future? Will novel technologies such as cryo-EM reveal high-affinity antibody binding sites?
- Would alternative treatment modalities, such as antibodies, siRNA or gene therapies, offer any advantages over small molecules?
- What are the roles of TRP channel splice variants under various disease conditions? Can cell compartment and or tissue-specific splice variants be therapeutically targeted?
- Is it possible to pharmacologically modulate intracellular TRP channels to treat chronic diseases such as lysosomal storage disease, neurodegenerative disease or intracellular pathogens through modulation of lysosomal TRP channels?
- Most TRP channel modulators are negative allosteric modulators (NAMs). We need to understand how a NAM interacts with the TRP channel activated by natural agonist in a given disease to build a quantitative PK-PD model of drug action in vivo. Do we understand well enough which endogenous agonists drive the disease process?
- TRPA1 in astrocytes was recently shown to be modulated by non-invasive, low-intensity, low-frequency ultrasound (LILFU)³⁰². Will LILFU open up new avenues for non-pharmacological modulation of a disease³⁰³? Could LILFU improve focused delivery of big molecules to the brain through the blood-brain barrier in a safe way?
- Can we use drugs that selectively activate (or block) phosphorylated (or otherwise post-translationally modified) TRP proteins? If so, can such selectivity mitigate adverse effects?
- Using our understanding of TRP channel structures³⁰⁴, can we design drugs that selectively target distinct functional states of TRP channels?

antagonist, XEN-D0501, is currently undergoing phase II clinical trials in T2DM patients with good tolerability and safety²⁹². A combined TRPV1 and TRPA1 antagonist may also protect sensory nerves and prevent cognitive decline in T2DM patients (BOX 2).

Conclusions

The huge interest of pharmaceutical companies in TRPV1 antagonists was based on two premises: first, the animal models in which capsaicin desensitization inhibited pain dramatically, and second, the belief that expression of TRPV1 was restricted to nociceptive fibres. Unfortunately, neither has turned out to be true. Those initial animal models are now recognized as poor predictors of clinical efficacy, and TRPV1 expression is much broader than initially thought. Despite these disappointments, the TRP family remains an exciting and potentially rewarding group of therapeutic targets for a broad range of diseases. Clearly, the one-size-fits-all approach

is not feasible and tests need to be developed to identify patient subgroups that may benefit from the therapy. Current TRP channel-modulator drug discovery efforts are guided by human genetics to allow identification of specific indications and patient groups that could benefit from pharmacotherapy (BOX 3). Furthermore, appropriate target engagement and safety biomarker studies should help define clinically meaningful doses and therapeutic windows. Central unwanted side effects may be minimized by using peripherally restricted antibodies, antibody–drug conjugates, and engineered proteins, whereas systemic adverse effects can be avoided by targeted, site-specific therapy (BOX 4). We predict that novel treatment modalities, such as engineered proteins, oligonucleotides and gene-based therapies, will be increasingly explored to treat human TRP channel-associated diseases in the future.

Published online 15 September 2021

- Cosens, D. J. & Manning, A. Abnormal electroretinogram from a *Drosophila* mutant. *Nature* **224**, 285–287 (1969).
This article represents the birth of TRP channels with the discovery of a mutant fruit fly that responds to sustained light stimulation with a transient current ('transient receptor potential') instead of the usual sustained response.
- Montell, C. & Rubin, G. M. Molecular characterization of the drosophila trp locus: a putative integral membrane protein required for phototransduction. *Neuron* **2**, 1313–1323 (1989).
- Wu, L. J., Sweet, T. B. & Clapham, D. E. International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. *Pharmacol. Rev.* **62**, 381–404 (2010).
- Nilius, B. & Szallasi, A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. *Pharmacol. Rev.* **66**, 676–814 (2014).
- Kashio, M. et al. Redox signal-mediated sensitization of transient receptor potential melastatin 2 (TRPM2) to temperature affects macrophage functions. *Proc. Natl Acad. Sci. USA* **109**, 6745–6750 (2012).
- Mittermeier, L. et al. TRPM7 is the central gatekeeper of intestinal mineral absorption essential for postnatal survival. *Proc. Natl Acad. Sci. USA* **116**, 4706–4715 (2019).
- McKemy, D. D., Neuhauser, W. M. & Julius, D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. *Nature* **416**, 52–58 (2002).
- Peier, A. M. et al. A TRP channel that senses cold stimuli and menthol. *Cell* **108**, 705–715 (2002).
McKemy et al. (2002) and Peier et al. (2002) describe the discovery of the cold-responsive TRP channel, TRPM8.
- Bidaux, G. et al. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. *Endocr. Relat. Cancer* **12**, 367–382 (2005).
- Caterina, M. J. et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**, 816–824 (1997).
This article describes the cloning of the long-sought-after capsaicin (vanilloid) receptor, which turned out to be a heat-activated channel.
- Jordt, S. E. & Julius, D. Molecular basis for species-specific sensitivity to “hot” chili peppers. *Cell* **108**, 421–430 (2002).
- Chu, Y., Cohen, B. E. & Chuang, H. H. A single amino acid controls species sensitivity to capsaicin. *Sci. Rep.* **10**, 8038 (2020).
- Mishra, S. K., Tisel, S. M., Orestes, P., Bhangoo, S. K. & Hoon, M. A. TRPV1-lineage neurons are required for thermal sensation. *EMBO J.* **30**, 582–593 (2011).
- Laursen, W. J., Schneider, E. R., Merriman, D. K., Bagriantsev, S. N. & Gracheva, E. O. Low-cost functional plasticity of TRPV1 supports heat tolerance in squirrels and camels. *Proc. Natl Acad. Sci. USA* **113**, 11342–11347 (2016).
- Laursen, W. J., Anderson, E. O., Hoffstaetter, L. J., Bagriantsev, S. N. & Gracheva, E. O. Species-specific temperature sensitivity of TRPA1. *Temperature* **11**, 214–226 (2015).
- Szallasi, A. & Blumberg, P. M. Vanilloid (capsaicin) receptors and mechanisms. *Pharmacol. Rev.* **51**, 160–211 (1999).
- Yarmolinsky, D. A. et al. Coding and plasticity in the mammalian thermosensory system. *Neuron* **92**, 1079–1092 (2016).
- Paricio-Montesinos, R. et al. The sensory coding of warm perception. *Neuron* **106**, 830–841 (2020).
This paper identifies two distinct neuronal populations that signal ‘warm’: warmth perception excites one population and, conversely, suppresses another with ongoing cool-drive firing.
- Tóth, B. I., Szallasi, A. & Biró, T. Transient receptor potential channels and itch: how deep should we scratch? *Handb. Exp. Pharmacol.* **226**, 89–133 (2015).
- Mezey, E. et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. *Proc. Natl Acad. Sci. USA* **97**, 3655–3660 (2000).
- Fernandes, E. S., Fernandes, M. A. & Keeble, J. E. The functions of TRPA1 and TRPV1: moving away from sensory nerves. *Br. J. Pharmacol.* **166**, 510–521 (2012).
- Romanovsky, A. A. The transient receptor potential vanilloid-1 channel in thermoregulation: a thermosensor it is not. *Pharmacol. Rev.* **61**, 228–261 (2009).
- Szolcsányi, J. Effect of capsaicin on thermoregulation: an update with new aspects. *Temperature* **2**, 277–296 (2015).
- Yonghak, P., Miyata, S. & Kuganov, E. TRPV1 is crucial for thermal homeostasis in the mouse by heat loss behaviors under warm ambient temperature. *Sci. Rep.* **10**, 8799 (2020).
- Szallasi, A., Cortright, D. N., Blum, C. A. & Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. *Nat. Rev. Drug Discov.* **6**, 357–372 (2007).
- Garami, A. et al. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis. *Pharmacol. Ther.* **208**, 107474 (2020).
- Garami, A. et al. TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development. *Acta Physiol.* **223**, e13038 (2018).
- Garami, A. et al. Transient receptor potential vanilloid 1 antagonists prevent anesthesia-induced hypothermia and decrease postincisional opioid dose requirements in rodents. *Anesthesiology* **127**, 813–823 (2017).
- Catalina Pharma. *A pharmacological way to treat perioperative hypothermia* <https://www.catalinapharma.com> (2017).
- Cao, Z. et al. TRPV1-mediated pharmacological hypothermia promotes improved functional recovery following ischemic stroke. *Sci. Rep.* **7**, 17685 (2017).
This preclinical study suggests that TRPV1 agonist may be beneficial in patients with ischaemic stroke by inducing pharmacological hypothermia.
- Benítez-Angeles, M., Morales-Lázaro, S. L., Juárez-González, E. & Rosenbaum, T. TRPV1: structure, endogenous agonists, and mechanisms. *Int. J. Mol. Sci.* **21**, 3421 (2020).
- Gao, Y., Cao, E., Julius, D. & Cheng, Y. TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. *Nature* **534**, 347–351 (2016).
- Lin King, J. V. et al. A cell-penetrating scorpion toxin enables mode-specific modulation of TRPA1 and pain. *Cell* **178**, 1362–1374 (2020).
- Hong, S., Zheng, G. & Wiley, J. W. Epigenetic regulation of genes that modulate chronic stress-induced visceral pain in the peripheral nervous system. *Gastroenterology* **148**, 148–157 (2015).
- Agarwal, N. et al. SUMOylation of enzymes and ion channels in sensory neurons protects against metabolic dysfunction, neuropathy, and sensory loss in diabetes. *Neuron* **107**, 1141–1159.e7 (2020).
- Bell, J. T. et al. Differential methylation of the TRPA1 promoter in pain sensitivity. *Nat. Commun.* **5**, 2978 (2014).
This article demonstrates for the first time that epigenetic regulation of a TRP channel can affect pain response.
- Gombert, S. et al. Transient receptor potential ankyrin 1 promoter methylation and peripheral pain sensitivity in Crohn’s disease. *Clin. Epigenet.* **12**, 1 (2019).
- White, J. P. M. et al. TRPV4: molecular conductor of a diverse orchestra. *Physiol. Rev.* **96**, 911–973 (2016).
- Gava, N. R. Reduced TRPM8 expression underpins reduced migraine risk and attenuated cold pain sensation in humans. *Sci. Rep.* **9**, 19655 (2019).
This article reveals TRPM8 to be a promising drug target in migraine.
- Patapoutian, A., Tate, S. & Woolf, C. J. Transient receptor potential channels: targeting pain at the source. *Nat. Rev. Drug Discov.* **8**, 55–68 (2009).
- Noto, C., Pappagallo, M. & Szallasi, A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. *Curr. Opin. Investig. Drugs* **10**, 702–710 (2009).
- Bonezzi, C. et al. Capsaicin 8% dermal patch in clinical practice: an expert opinion. *Exp. Opin. Pharmacother.* **21**, 1377–1387 (2020).
- Chung, M. K. & Campbell, J. N. Use of capsaicin to treat pain: mechanistic and therapeutic considerations. *Pharmaceuticals* **9**, 66 (2016).
- Sidenius, P. The axonopathy of diabetic neuropathy. *Diabetes* **31**, 356–363 (1982).
- Brand, L. et al. NE-19550: a novel, orally active anti-inflammatory agent. *Drugs Exp. Clin. Res.* **13**, 259–265 (1987).

46. Ann, J. et al. Discovery of nonpungent transient potential receptor vanilloid 1 (TRPV1) agonist as strong topical analgesic. *J. Med. Chem.* **63**, 418–424 (2020).
47. Brown, D. C. Resiniferatoxin: the evolution of the “molecular scalpel” for chronic pain relief. *Pharmaceuticals* **9**, 47 (2016).
48. US National Library of Medicine. A phase 3 study to evaluate the efficacy and safety of resiniferatoxin for pain due to osteoarthritis of the knee. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT04044742> (2019).
49. US National Library of Medicine. Resiniferatoxin to treat severe pain associated with advanced cancer. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT00804154> (2008).
50. Brown, D. C. et al. Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. *Anesthesiology* **103**, 1052–1059 (2005).
- This article is the first preclinical study that paved the way to clinical trials using intrathecal resiniferatoxin to achieve permanent analgesia in patients with cancer pain.**
51. Heiss, N. et al. A phase I study of the intrathecal administration of resiniferatoxin for treating severe refractory pain associated with advanced cancer. <http://sorrentotherapeutics.com/wp-content/uploads/2013/10/APS-poster-042514-Final.pdf> (NIH, 2014).
52. Appendino, G. & Szallasi, A. Clinically useful vanilloid receptor TRPV1 antagonists: just around the corner (or too early to tell)? *Prog. Med. Chem.* **44**, 145–180 (2006).
53. Moran, M. M. & Szallasi, A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. *Br. J. Pharmacol.* **175**, 2185–2203 (2018).
54. Gavva, N. R. et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. *J. Pharmacol. Exp. Ther.* **323**, 128–137 (2007).
55. Caterina, M. J. et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. *Science* **288**, 306–313 (2000).
56. Davis, J. B. et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. *Nature* **405**, 183–187 (2000).
57. Gavva, N. R. et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. *Pain* **136**, 202–210 (2008).
58. Eid, S. Therapeutic targeting of TRP channels: the TR(i)P to pain relief. *Curr. Top. Med. Chem.* **11**, 2118–2130 (2011).
59. Miller, F., Björnsson, M., Svensson, O. & Karlsten, R. Experiences with an adaptive design for a dose-finding study in patients with osteoarthritis. *Contemp. Clin. Trials* **37**, 189–199 (2014).
60. Long, W. et al. Vitamin D is an endogenous partial agonist of the transient receptor potential vanilloid 1 channel. *J. Physiol.* **598**, 4321–4338 (2020).
61. Manitpisitkul, P. et al. A multiple-dose, double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics, and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatriptan). *Scand. J. Pain* **18**, 151–164 (2018). **This paper reports the first clinical study demonstrating analgesic potential for a TRPV1 antagonist.**
62. Arsenault, P. et al. NEO6860, a modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritic knee pain. *Pain. Rep.* **3**, e696 (2018).
63. Damann, N. et al. *In vitro* characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) receptor inhibitor GRTE 16523. *Eur. J. Pharmacol.* **871**, 172934 (2020).
64. Gu, Y., Li, G. & Huang, L.-Y. M. Inflammation induces Epac-protein kinase C alpha and epsilon signaling in TRPV1-mediated hyperalgesia. *Pain* **159**, 2383–2393 (2018).
65. Joseph, J. et al. Phosphorylation of the TRPV1 S801 contributes to modality-specific hyperalgesia in mice. *J. Neurosci.* **39**, 9954–9966 (2019).
66. Hoffmeister, C. et al. Participation of TRPV1 receptor in the development of acute gout attacks. *Rheumatology* **53**, 240–249 (2014).
67. Yin, C. et al. Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. *Br. J. Pharmacol.* **177**, 2042–2057 (2020).
68. Urata, K. et al. Involvement of TRPV1 and TRPA1 in incisional intraoral and extraoral pain. *J. Dent. Res.* **94**, 446–454 (2015).
69. Ossola, C. A. et al. A new target to ameliorate the damage of periodontal disease: the role of transient receptor potential vanilloid type-1 in contrast to that of specific cannabinoid receptors in rats. *J. Periodontol.* **90**, 1325–1335 (2019).
70. Bohonyi, N. et al. Local upregulation of transient receptor potential ankyrin-1 and transient receptor potential vanilloid-1 channels in rectosigmoid deep infiltrating endometriosis. *Mol. Pain.* **13**, 1744806917705564 (2017).
71. Ramesh, D., D’Agata, A., Starkweather, A. R. & Young, E. E. Contribution of endocannabinoid gene expression and genotype on low back pain susceptibility and chronicity. *Clin. J. Pain.* **34**, 8–14 (2018).
72. Kim, H., Mittal, D. P., Iadarola, M. J. & Dionne, R. A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. *J. Med. Genet.* **43**, e40 (2006).
73. Jhun, E. H. et al. Transient receptor potential polymorphism and haplotype associate with crisis pain in sickle cell disease. *Pharmacogenetics* **19**, 401–411 (2018).
74. Nirenberg, M. J., Chaoui, R., Biller, T. M., Gilbert, R. M. & Paisán-Ruiz, C. A novel TRPA1 variant is associated with carbamazepine-responsive cramp-fasciculation syndrome. *Clin. Genet.* **93**, 164–168 (2018).
75. Kremeyer, B. et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. *Neuron* **66**, 671–680 (2010).
- This article described the first genetic evidence implying a causative role for TRPA1 in human pain.**
76. Naert, R., Talavera, A., Startek, J. B. & Talavera, K. TRPA1 gene variants hurting our feelings. *Pflügers Arch.* **472**, 953–960 (2020).
77. Bessac, B. F. & Jordt, S.-E. Breathtaking TRP channels: TRPA1 and TRPV1 in airway chemosensation and reflex control. *Physiology* **23**, 360–370 (2008).
78. Moran, M. M., McAlexander, M. A., Biró, T. & Szallasi, A. Transient receptor potential channels as therapeutic targets. *Nat. Rev. Drug Discov.* **10**, 601–620 (2011).
79. Eberhardt, M. J. et al. Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies. *J. Biol. Chem.* **287**, 28291–28306 (2012). **This study provides a mechanistic explanation for the neuropathic pain that develops in patients with long-standing diabetes, and pinpoints TRPA1 as a potential preventive target.**
80. Ohkawara, S., Tanaka-Kagawa, T., Furukawa, Y. & Jinno, H. Methylglyoxal activates the human transient receptor potential ankyrin 1 channel. *J. Toxicol. Sci.* **37**, 831–835 (2012).
81. Shimizu, S., Takahashi, N. & Mori, Y. TRPs as chemosensors (ROS, RNS, RCS, gasotransmitters). *Handb. Exp. Pharmacol.* **223**, 767–794 (2014).
82. Hinman, A., Chuang, H. H., Bautista, D. M. & Julius, D. TRP channel activation by reversible covalent modification. *Proc. Natl Acad. Sci. USA* **103**, 19564–19568 (2006).
83. Nassini, R. et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* **152**, 1621–1631 (2011).
84. De Logu, F. et al. Macrophages and Schwann cell TRPA1 mediate chronic allodynia in a mouse model of complex regional pain syndrome type I. *Brain Behav. Immun.* **88**, 535–546 (2020).
85. Vermeulen, W. et al. The role of TRPV1 and TRPA1 in visceral hypersensitivity to colorectal distension during experimental colitis in rats. *Eur. J. Pharmacol.* **698**, 404–412 (2013).
86. Reese, R. M. et al. Behavioral characterization of CRISPR-generated TRPA1 knockout rat in models of pain, itch, and asthma. *Sci. Rep.* **10**, 979 (2020).
87. Koivisto, A., Jalava, N., Bratty, R. & Pertovaara, A. TRPA1 antagonists for pain relief. *Pharmaceuticals* **11**, 117 (2018).
88. Koivisto, A. et al. Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in diabetic animals: sustained activation of TRPA1 channel contributes to the pathogenesis of peripheral diabetic neuropathy. *Pharmacol. Res.* **65**, 149–158 (2012). **This preclinical study implies that pharmacological blockade of TRPA1 may protect sensory nerves and prevent the development of peripheral diabetic neuropathy.**
89. A phase 2, 4 week randomized, double-blind, parallel group, placebo controlled proof of concept study to evaluate efficacy, safety and tolerability of GRC 17536 in patients with painful diabetic peripheral neuropathy. *EU Clinical Trials Register* <https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002320-33/results> (2021).
90. de David Antoniazzi, C. T. et al. Topical treatment with a transient receptor potential ankyrin 1 (TRPA1) antagonist reduced nociception and inflammation in a thermal lesion model in rats. *Eur. J. Pharm. Sci.* **125**, 28–38 (2018).
91. Petrus, M. et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. *Mol. Pain.* **3**, 40 (2007).
92. Kissin, I., Davison, N. & Bradley, E. L. Jr. Perineural resiniferatoxin prevents hyperalgesia in a rat model of postoperative pain. *Anesth. Analg.* **100**, 774–780 (2005).
93. Szallasi, A. Vanilloid-sensitive neurons: a fundamental subdivision of the peripheral nervous system. *J. Periph. Nerv. Syst.* **1**, 6–18 (1996).
94. Lilly. Lilly to acquire pre-clinical pain program from Hydra Biosciences. <https://prnewswire.com/news-releases/lilly-to-acquire-pre-clinical-pain-program-from-hydra-biosciences-300765876.html> (2018).
95. Chen, H. & Terrett, J. A. Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015–2019). *Expert Opin. Ther. Pat.* **30**, 643–657 (2020).
96. Bautista, D. M. et al. The menthol receptor TRPM8 is the principal detector of environmental cold. *Nature* **448**, 204–208 (2007).
97. Knowlton, W. M., Bifolck-Fisher, A., Bautista, D. M. & McKemy, D. D. TRPM8, but not TRPA1, is required for neural and behavioral responses to acute noxious cold temperatures and cold-mimetics in vivo. *Pain* **150**, 340–350 (2010).
98. Weyer, A. D. & Lehto, S. G. Development of TRPM8 antagonists to treat chronic pain and migraine. *Pharmaceuticals* **10**, 37 (2017).
99. Reimünde, A. et al. Deletion of the cold thermoreceptor TRPM8 increases heat loss and food intake, leading to reduced body temperature and obesity in mice. *J. Neurosci.* **38**, 3643–3656 (2018).
100. Winchester, W. J. et al. Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. *J. Pharmacol. Exp. Ther.* **351**, 259–269 (2014).
101. Horne, D. B. et al. Discovery of TRPM8 antagonist (S)-6-(((3-fluoro-4-(trifluoromethoxy)phenyl)[3-fluoropyridin-2-yl]methyl)carbamoyl)nicotinic acid (AMG 353), a clinical candidate for the treatment of migraine. *J. Med. Chem.* **61**, 8186–8201 (2018).
102. Amato, A., Terzo, S., Lentini, L., Marchesa, P. & Mulé, F. TRPM8 channel activation reduces the spontaneous contractions in distal human colon. *Int. J. Mol. Sci.* **21**, 5403 (2020).
103. Lin, Z. et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. *Am. J. Hum. Genet.* **90**, 558–564 (2012). **This article reports the identification of a TRPV3 gene defect that causes a human disease.**
104. Duchatelet, S. et al. A new TRPV3 missense mutation in a patient with Olmsted syndrome and erythromelalgia. *JAMA Dermatol.* **150**, 303–306 (2014).
105. Peters, F., Kopp, J., Fischer, J. & Tantcheva-Poór, I. Mutation in TRPV3 causes painful focal plantar keratoderma. *J. Acad. Eur. Dermatol. Venereol.* **34**, e620–e622 (2020).
106. Facer, P. et al. Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4, and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. *BMC Neurol.* **7**, 11 (2007).
107. Broad, L. M. et al. TRPV3 in drug development. *Pharmaceuticals* **9**, 55 (2016).
108. Cenac, N. et al. Transient receptor potential vanilloid-4 has a major role in visceral hypersensitivity symptoms. *Gastroenterology* **135**, 937–946 (2008).
109. Kanju, P. et al. Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain. *Sci. Rep.* **6**, 26894 (2016).
110. Schwatz, E. S. et al. TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic inflammation and pain in chronic pancreatitis. *J. Neurosci.* **33**, 5603–5611 (2013).
111. Wang, H., Song, T., Wang, W. & Zhang, Z. TRPM2 participates the transformation of acute pain to chronic pain during injury-induced neuropathic pain. *Synapse* **73**, e22117 (2019).
112. Wick, E. C. et al. Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **290**, G959–G969 (2006).

113. Schwartz, E. S. et al. TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic pain in chronic pancreatitis. *J. Neurosci.* **33**, 5603–5611 (2013).
114. Haraguchi, K. et al. TRPM2 contributes to inflammatory and neuropathic pain through the aggravation pronociceptive inflammatory responses in mice. *J. Neurosci.* **32**, 3931–3941 (2012).
115. Vriens, J. et al. TRPM3 is a nociceptor channel involved in the detection of noxious heat. *Neuron* **70**, 482–494 (2011).
116. Vandewauw, I. et al. A TRP channel trio mediates acute noxious heat sensing. *Nature* **555**, 662–666 (2018).
- This article describes how, in mice, eliminating pain responses to harmful heat requires a triple knockout of the TRPA1, TRPV1 and TRPM3 genes, suggesting a high degree of redundancy; the triple knockout mouse retains noxious cold and mechanical sensing and preference for moderate temperatures.**
117. Su, S., Yudin, Y., Kim, N., Tao, Y.-X. & Rohacs, T. TRPM3 channels play roles in heat hypersensitivity and spontaneous pain after nerve injury. *J. Neurosci.* **41**, 3457–2474 (2021).
118. Straub, I. et al. Flavanones that selectively inhibit TRPM3 attenuate thermal nociception in vivo. *Mol. Pharmacol.* **84**, 736–750 (2013).
119. Jia, S., Zhang, Y. & Yu, J. Antinociceptive effects of isosakuranetin in a rat model of peripheral neuropathy. *Pharmacology* **100**, 201–207 (2017).
120. Yao, Q., Lin, M.-T., Zhu, Y.-D., Xu, H.-L. & Zhao, Y.-Z. Recent trends in potential therapeutic applications of the dietary flavonoid didymin. *Molecules* **23**, 2547 (2018).
121. Buniel, M., Wisnoskey, B., Glazebrook, P. A., Schilling, W. P. & Kunze, D. L. Distribution of TRPC channels in the visceral sensory pathway. *Novartis Found. Symp.* **258**, 236–243 (2004).
122. Sadler, K. E. et al. Transient receptor potential canonical 5 mediates inflammatory mechanical and spontaneous pain in mice. *Sci. Transl. Med.* **13**, eabd7702 (2021).
- This article reports TRPC5 to be a promising pain target.**
123. Westlund, K. N. et al. A rat knockout model implicates TRPC4 in visceral pain sensation. *Neuroscience* **262**, 165–175 (2014).
124. Miller, M. et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. *J. Biol. Chem.* **286**, 33436–33446 (2011).
125. Chen, Y. et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. *Gastroenterology* **161**, 301–317.e16 (2021).
126. Blum, T. et al. Trpc5 deficiency causes hypoprolactinemia and altered functions of oscillatory dopamine neurons in the arcuate nucleus. *Proc. Natl Acad. Sci. USA* **116**, 15236–15243 (2019).
127. Wei, H., Sagalajev, B., Yüzer, M. A., Koivisto, A. & Pertovaara, A. Regulation of neuropathic pain behavior by amygdaloid TRPC4/C5 channels. *Neurosci. Lett.* **608**, 12–17 (2015).
128. Belvisi, M. G. & Birrell, M. A. The emerging role of transient receptor potential channels in chronic lung disease. *Eur. Respir. J.* **50**, 1601357 (2017).
129. Collier, J. G. & Fuller, R. W. Capsaicin inhalation in man and the effects of sodium cromoglycate. *Br. J. Pharmacol.* **81**, 113–117 (1984).
130. Belvisi, M. G. et al. Neurophenotypes in airway diseases. Insights from translational cough studies. *Am. J. Respir. Crit. Care Med.* **193**, 1364–1372 (2016).
131. Grace, M., Birrell, M. A., Dubuis, E., Maher, S. A. & Belvisi, M. G. Transient receptor potential channels mediate the tussive response to prostaglandin E2 and bradykinin. *Thorax* **67**, 891–900 (2012).
132. Zhang, G., Lin, R.-L., Wiggers, M., Snow, D. M. & Lee, L.-Y. Altered expression of TRPV1 and sensitivity to capsaicin in pulmonary myelinated afferents following chronic airway inflammation in the rat. *J. Physiol.* **586**, 5771–5786 (2008).
133. Lieu, T. M., Myers, A. C., Meeker, S. & Udem, B. J. TRPV1 induction in airway vagal low-threshold mechanosensory neurons by allergen challenge and neurotrophic factors. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **302**, L941–L948 (2012).
134. Smit, L. A. M. et al. Transient receptor potential genes, smoking, occupational exposures and cough in adults. *Respir. Res.* **13**, 26 (2012).
135. Khalid, J. et al. Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind, randomized, controlled trial. *J. Allergy Clin. Immunol.* **134**, 56–62 (2014).
136. Belvisi, M. G. et al. XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough. *Am. J. Respir. Crit. Care Med.* **196**, 1255–1263 (2017).
137. Smith, J. A. et al. TRPV1 antagonism with XEN-D0501 in chronic obstructive pulmonary disease: translation from pre-clinical model to clinical trial. *Am. J. Respir. Crit. Care Med.* **195**, A6339 (2017).
138. Grace, M. S., Baxter, M., Dubuis, E., Birrell, M. A. & Belvisi, M. G. Transient receptor potential (TRP) channels in the airway: role in airway disease. *Br. J. Pharmacol.* **171**, 2593–2607 (2014).
139. McGravey, L. P. et al. Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. *J. Allergy Clin. Immunol.* **133**, 704–712 (2014).
140. Yu, H., Li, Q., Kolosov, V. P., Perelman, J. M. & Zhou, X. Regulation of particulate matter-induced mucin secretion by transient receptor potential vanilloid 1 receptors. *Inflammation* **35**, 1851–1859 (2012).
141. Reilly, C. A. et al. Calcium-dependent and independent mechanisms of capsaicin receptor (TRPV1)-mediated cytokine production and cell death in human bronchial epithelial cells. *J. Biochem. Mol. Toxicol.* **19**, 266–275 (2005).
142. Baxter, M. et al. Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung. *Thorax* **69**, 1080–1089 (2014).
143. Baker, K. et al. Role of the ion channel, transient receptor potential cation channel subfamily V member 1 (TRPV1), in allergic asthma. *Respir. Res.* **17**, 67 (2016).
144. Delescluse, I., Mace, H. & Adcock, J. J. Inhibition of airway hyper-responsiveness by TRPV1 antagonists (SB-705498 and PF-04065463) in the unanesthetized, ovalbumin-sensitized guinea pig. *Br. J. Pharmacol.* **166**, 1822–1832 (2012).
145. Bessac, B. F. et al. TRPA1 is a major oxygen sensor in murine airway sensory neurons. *J. Clin. Invest.* **118**, 1899–1990 (2008).
146. Birrell, M. A. et al. TRPA1 agonists evoke coughing in guinea pig and human volunteers. *Am. J. Respir. Crit. Care Med.* **180**, 1042–1047 (2009).
147. Mukhopadhyay, I. et al. Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. *PLoS ONE* **9**, e97005 (2014).
148. Andre, E. et al. Transient receptor potential ankyrin receptor 1 is a novel target for pro-tussive agents. *Br. J. Pharmacol.* **158**, 1621–1628 (2009).
149. Mukhopadhyay, I. et al. Expression of functional TRPA1 receptor on human lung fibroblast and epithelial cells. *J. Recept. Signal. Transduct. Res.* **31**, 350–358 (2011).
150. Bandell, M. et al. Noxious cold ion channel is activated by pungent compounds and bradykinin. *Neuron* **41**, 848–857 (2004).
151. Bautista, D. M. et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. *Cell* **124**, 1269–1282 (2006).
152. Andre, E. et al. Cigarette smoke-induced neurogenic inflammation is mediated by α , β -unsaturated aldehydes and the TRPA1 receptor in rodents. *J. Clin. Invest.* **118**, 2574–2582 (2008).
153. Taylor-Clark, T. E. Role of reactive oxygen species and TRP channels in the cough reflex. *Oxid. Calcium* **60**, 155–162 (2016).
154. Robinson, R. K. et al. Mechanistic link between diesel exhaust particles and respiratory reflexes. *J. Allergy Clin. Immunol.* **141**, 1074–1084 (2018).
155. Profita, M. et al. Increased prostaglandin E2 concentrations and cyclooxygenase-2 expression in asthmatic subjects with sputum eosinophilia. *J. Allergy Clin. Immunol.* **112**, 709–716 (2003).
156. MacNee, W. et al. Evaluation of exhaled breath condensate pH as a biomarker for COPD. *Respir. Med.* **105**, 1037–1045 (2011).
157. Tevisani, M. et al. Antitussive activity of iodo-neriferatoxin in guinea pigs. *Thorax* **59**, 769–772 (2004).
158. Kollarik, M., Ru, F. & Udem, B. Acid-sensitive vagal sensory pathways and cough. *Pulm. Pharmacol. Ther.* **20**, 402–411 (2007).
159. Raemdonck, K. et al. A role for sensory nerves in the late asthmatic response. *Thorax* **67**, 19–25 (2012).
160. Caceres, A. I. et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. *Proc. Natl Acad. Sci. USA* **106**, 9099–9104 (2009).
161. Taylor-Clark, T. E., Kiros, F., Carr, M. J. & McAlexander, M. A. Transient receptor potential ankyrin 1 mediates toluene diisocyanate-evoked respiratory irritation. *Am. J. Respir. Cell. Mol. Biol.* **40**, 756–762 (2009).
162. Fabbri, L. M. et al. Prednisone inhibits late asthmatic reactions and the associated increase in airway responsiveness induced by toluene-diisocyanate in sensitized subjects. *Am. Rev. Respir. Dis.* **132**, 1010–1014 (1985).
163. Hox, V. et al. Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. *Am. J. Respir. Crit. Care Med.* **187**, 486–493 (2013).
164. WHO. *Pneumonia*. <https://www.who.int/en/news-room/fact-sheets/detail/pneumonia> (2015).
165. Meseguer, V. et al. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. *Nat. Commun.* **5**, 3125 (2014).
166. Gallo, V. et al. TRPA1 gene polymorphisms and childhood asthma. *Pediatr. Allergy Immunol.* **28**, 191–198 (2017).
167. Pretti, D., Saponaro, G. & Szallasi, A. Transient receptor potential ankyrin 1 (TRPA1) antagonists. *Pharm. Pat. Anal.* **4**, 75–94 (2015).
168. Mukhopadhyay, I., Kulkarni, A. & Khairatkar-Joshi, N. Blocking TRPA1 in respiratory disorders: does it hold a promise? *Pharmaceuticals* **9**, 70 (2016).
169. Balestrini, A. et al. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. *J. Exp. Med.* **218**, e20201637 (2021).
- This article reports a potent and orally bioavailable TRPA1 antagonist with good target engagement in humans that effectively blocks cough response, airway hyperreactivity and edema formation in preclinical models of asthma.**
170. Dietrich, A. Modulators of transient receptor potential (TRP) channels as therapeutic options in lung disease. *Pharmaceuticals* **12**, 23 (2019).
171. Scheraga, R. G., Southern, B. D., Grove, L. M. & Olman, M. A. The role of transient receptor potential vanilloid 4 in pulmonary inflammatory diseases. *Front. Immunol.* **8**, 503 (2017).
172. Grace, M. S., Bonvini, S. J., Belvisi, M. G. & McIntyre, P. Modulation of the TRPV4 ion channel as a therapeutic target for disease. *Pharmacol. Ther.* **177**, 9–22 (2017).
173. Alvarez, D. F. et al. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. *Circ. Res.* **99**, 988–995 (2006).
- This is one of the first articles in which TRPV4 is revealed as a key player in acute lung injury.**
174. Simonsen, U., Wandall-Frostholm, C., Viguera-Oliván, A. & Köhler, R. Emerging roles of calcium-activated K channels and TRPV4 channels in lung edema and pulmonary circulatory collapse. *Acta Physiol.* **219**, 176–187 (2017).
175. Hamanaka, K. et al. TRPV4 channels augment macrophage activation and ventilator-induced lung injury. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **299**, L353–L362 (2010).
176. Balakrishna, S. et al. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **307**, L158–L172 (2014).
177. Yeung, D. T., Harper, J. R. & Platoff, G. E. Jr The National Institutes of Health Countermeasures Research Program (NIH CCRP): a collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people. *Drug Dev. Res.* **81**, 907–910 (2020).
178. Thorneloe, K. S. et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. *Sci. Transl. Med.* **4**, 159ra148 (2012).
179. Kuebler, W. M., Jordt, S. E. & Liedtke, W. B. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **318**, L1239–L1243 (2020).
180. Bonvini, S. J. et al. Transient receptor potential cation channel, subfamily V, member 4 and airway sensory afferent activation: role of adenosine triphosphate. *J. Allergy Clin. Immunol.* **138**, 249–261 (2016).
181. Bonvini, S. J. et al. Novel airway smooth muscle-mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma. *Eur. Respir. J.* **56**, 1901458 (2020).

182. Seminario-Vidal, L. et al. Rho signaling regulates pannexin 1-mediated ATP release from airway epithelia. *J. Biol. Chem.* **286**, 26277–26286 (2011).
183. Abdulqawi, L. et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomized, double-blind, placebo-controlled phase 2 study. *Lancet* **385**, 1198–1205 (2015).
184. McAlexander, M. A., Luttmann, M. A., Hunsberger, G. E. & Udem, B. J. Transient receptor potential vanilloid 4 activation constricts the human bronchus via the release of cysteinyl leukotrienes. *J. Pharmacol. Exp. Ther.* **349**, 118–125 (2014).
185. Cantero-Recasens, G. et al. Loss of function of transient receptor potential vanilloid 1 (TRPV1) genetic variant is associated with lower risk of active childhood asthma. *J. Biol. Chem.* **285**, 27532–27535 (2010).
186. Zhu, G. et al. Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease. *Hum. Mol. Genet.* **18**, 2053–2062 (2009).
187. Rahaman, S. O. et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. *J. Clin. Invest.* **124**, 5225–5238 (2014).
188. Al-Azzam, N. et al. Transient receptor vanilloid channel regulates fibroblast differentiation and airway remodelling by modulating redox signals through NADPH oxidase 4. *Sci. Rep.* **10**, 9827 (2020).
189. Zhan, L. & Li, J. The role of TRPV4 in fibrosis. *Gene* **642**, 1–8 (2018).
190. Riteau, N. et al. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. *Am. J. Respir. Crit. Care Med.* **182**, 774–783 (2010).
191. Plevkova, J. et al. The role of trigeminal nasal TRPM8-expressing sensory neurons in the antitussive effects of menthol. *J. Appl. Physiol.* **115**, 268–274 (2013).
192. Morice, A. H., Marshall, A. E., Higgins, K. S. & Grattan, T. J. Effect of inhaled menthol on citric acid-induced cough in normal subjects. *Thorax* **49**, 1024–1026 (1994).
193. Wise, P. M., Breslin, P. A. S. & Dalton, P. Sweet taste and menthol increase cough reflex thresholds. *Pulm. Pharmacol. Ther.* **25**, 236–241 (2012).
194. Karashima, Y. et al. Bimodal action of menthol on the transient receptor potential channel TRPA1. *J. Neurosci.* **27**, 9874–9884 (2007).
195. Cruz, F. et al. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. *J. Urol.* **157**, 585–589 (1997).
196. Silva, C., Rio, M. E. & Cruz, F. Desensitization of bladder sensory fibers by intravesical resiniferatoxin, a capsaicin analog: long-term results for the treatment of detrusor hyperreflexia. *Eur. Urol.* **38**, 444–452 (2000).
197. Phé, V. et al. Intravesical vanilloids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS). *NeuroUrol. Urodyn.* **37**, 67–82 (2018).
198. Liu, B. L. et al. Increased severity of inflammation correlates with elevated expression of TRPV1 nerve fibers and nerve growth factor on interstitial cystitis/bladder pain syndrome. *Urol. Int.* **92**, 202–208 (2014).
199. Payne, S. K. et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. *J. Urol.* **173**, 1590–1594 (2005).
200. Shi, B. et al. Resiniferatoxin for the treatment of lifelong premature ejaculation: a preliminary study. *Int. J. Urol.* **21**, 923–926 (2014).
201. Charrua, A. et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. *J. Urol.* **181**, 379–386 (2009).
202. Aizawa, N. et al. RQ-00434739, a novel TRPM8 antagonist, inhibits prostaglandin E2-induced hyperactivity of the primary bladder afferent nerves in rats. *Life Sci.* **218**, 89–95 (2019).
203. Aizawa, N. et al. KPR-2579, a novel TRPM8 antagonist, inhibits acetic acid-induced bladder afferent hyperactivity in rats. *NeuroUrol. Urodyn.* **37**, 1633–1640 (2018).
204. Birder, L. et al. Activation of urothelial transient receptor potential vanilloid 4 by 4 α -phorbol 12, 13-didecanoate contributes to the altered bladder reflexes in the rat. *J. Pharmacol. Exp. Ther.* **323**, 227–235 (2007).
205. Gevaert, T. et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. *J. Clin. Invest.* **117**, 3453–3462 (2007).
206. Thorneloe, K. S. et al. N-((1S)-1-{[4-(2S)-2-[[[2,4-dichlorophenyl]sulfonyl]amino]-3-hydroxypropanoyl]-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: part I. *J. Pharmacol. Exp. Ther.* **326**, 432–442 (2008).
207. Roberts, M. W. G. et al. TRPV4 receptor as a functional sensory molecule in bladder urothelium: stretch-independent, tissue-specific actions and pathological implications. *FASEB J.* **34**, 263–286 (2020).
208. Deruyver, Y. et al. Intravesical activation of the cation channel TRPV4 improves bladder function in a rat model for detrusor underactivity. *Eur. Urol.* **74**, 336–345 (2018).
209. Everaerts, W. et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. *Proc. Natl Acad. Sci. USA* **107**, 19084–19089 (2010).
210. Zhou, Y. et al. A small molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models. *Science* **358**, 1332–1336 (2017). **This study provides a proof-of-principle that chemical inhibition of TRPC5 channel activity can provide a therapeutic benefit in a rodent model of focal segmental glomerulosclerosis (FSGS).**
211. Lin, B. L. et al. In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease. *Proc. Natl Acad. Sci. USA* **116**, 10156–10161 (2019).
212. Wang, L., Chang, J. H., Buckley, A. F. & Spurney, R. F. Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice. *Kidney Int.* **95**, 321–332 (2019).
213. Riehle, M. et al. TRPC6 G757D loss-of-function mutation associates with FSGS. *J. Am. Soc. Nephrol.* **27**, 2771–2783 (2016).
214. Caterina, M. J. & Pang, Z. TRP channels in skin biology and pathophysiology. *Pharmaceuticals* **9**, 77 (2016).
215. Zhou, Y. et al. Transient receptor potential ankyrin 1 (TRPA1) positively regulates imiquimod-induced psoriasisform dermal inflammation in mice. *J. Cell. Mol. Med.* **23**, 4819–4828 (2019).
216. Yoshioka, T. et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. *J. Invest. Dermatol.* **129**, 714–722 (2009).
217. Kim, H. O. et al. Increased activity of TRPV3 in keratinocytes in hypertrophic burn scars with postburn pruritus. *Wound Repair. Regen.* **24**, 841–850 (2016).
218. Luo, J. et al. Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and non-allergic chronic itch. *J. Allergy Clin. Immunol.* **141**, 608–619 (2018).
219. Akiyama, T. et al. Involvement of TRPV4 in serotonin-evoked scratching. *J. Invest. Dermatol.* **136**, 154–160 (2016).
220. Misery, L. et al. Real-life study of anti-itching effects of a cream containing menthoxypropioneol, a TRPM8 agonist, in atopic dermatitis patients. *J. Eur. Acad. Dermatol. Venereol.* **33**, e67–e69 (2019).
221. Lee, Y. W. et al. Efficacy and safety of PAC-14028 cream, a novel, topical, non-steroidal, selective TRPV1 antagonist in patients with mild- to moderate atopic dermatitis: a phase IIb randomized trial. *Br. J. Dermatol.* **180**, 1030–1038 (2019).
222. Cohen, J. A. et al. Cutaneous TRPV1⁺ neurons trigger protective innate type 17 anticipatory immunity. *Cell* **178**, 919–932 (2019).
223. Fialho, M. F. P. et al. Topical transient receptor potential ankyrin 1 antagonist treatment attenuates nociception and inflammation in ultraviolet B radiation-induced burn model in mice. *J. Dermatol. Sci.* **97**, 135–142 (2020).
224. Cheng, X. et al. TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. *Cell* **141**, 331–343 (2010).
225. Asakawa, M. et al. Association of a mutation in TRPV3 with defective hair growth in rodents. *J. Invest. Dermatol.* **126**, 2664–2672 (2006).
226. Borbír, I. et al. Activation of transient receptor potential vanilloid-3 inhibits human hair growth. *J. Invest. Dermatol.* **131**, 1605–1614 (2011).
227. Imura, K., Yoshioka, T., Hirasawa, T. & Sakata, T. Role of TRPV3 in immune response to development of dermatitis. *J. Inflamm.* **6**, 17 (2009).
228. Szántó, M. et al. Activation of TRPV3 inhibits lipogenesis and stimulates production of inflammatory mediators in human sebocytes: a putative contributor to dry skin dermatoses. *J. Invest. Dermatol.* **139**, 250–253 (2019).
229. Zhou, Y. et al. TRPV1 mediates inflammation and hyperplasia in imiquimod (IMQ)-induced psoriasisform dermatitis (PsD) in mice. *J. Dermatol. Sci.* **92**, 264–271 (2018).
230. Chen, Y. et al. TRPV4 moves toward centerfold in rosacea pathogenesis. *J. Invest. Dermatol.* **137**, 801–804 (2017).
231. Wang, H. et al. Gain-of-function mutations in TRPM4 activation gate cause progressive symmetric erythrokeratoderma. *J. Invest. Dermatol.* **139**, 1089–1097 (2019).
232. Yang, J. M., Wei, E. T., Kim, S. J. & Yoon, K. C. TRPM8 channels and dry eye. *Pharmaceuticals* **11**, 125 (2018).
233. Okada, Y. et al. Loss of TRPV4 function suppresses inflammatory astrocytosis induced by alkali-burning mouse corneas. *PLoS ONE* **11**, e0167200 (2016).
234. Kwon, J. Y., Lee, H. S. & Joo, C.-K. TRPV1 antagonist suppresses allergic conjunctivitis in a murine model. *Ocul. Immunol. Inflamm.* **26**, 440–448 (2018).
235. Jang, Y. et al. Quantitative analysis of TRP channel genes in mouse organs. *Arch. Pharm. Res.* **35**, 1823–1830 (2012).
236. Shigetomi, E., Jackson-Weaver, O., Huckstepp, R. T., O'Dell, T. J. & Khakh, B. S. TRPA1 channels are regulators of astrocyte basal calcium levels and long term potentiation via constitutive D-serine release. *J. Neurosci.* **33**, 10143–10153 (2013).
237. Kheradpehrouh, E., Tang, M. F., Mattingley, J. B. & Arabzadeh, E. Enhanced sensory coding in mouse vibrissal and visual cortex through TRPA1. *Cell Rep.* **32**, 107935 (2020).
238. Wagner Pires, P. & Earley, S. Neuroprotective effects of TRPA1 channels in the cerebral endothelium following ischemic stroke. *eLife* **7**, e35316 (2018). **This paper shows that the TRPA1 agonist cinnamaldehyde reduced infarct in wild-type mice, whereas *Trpa1* deletion in endothelial cells increased cerebral infarcts and eliminated the effects of cinnamaldehyde, revealing the therapeutic potential of TRPA1 activation to reduce ischaemic brain damage.**
239. De Logu, F. et al. Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice. *Nat. Commun.* **8**, 1887 (2017).
240. Hamilton, N. B., Kolodziejczyk, K., Kougioumtzidou, E. & Attwell, D. Proton-gated Ca²⁺-permeable TRP channels damage myelin in conditions mimicking ischemia. *Nature* **529**, 523–527 (2016).
241. Sáhgy, É. et al. TRPA1 deficiency is protective in cuprizone-induced demyelination — a new target against oligodendrocyte apoptosis. *Glia* **64**, 2166–2180 (2016).
242. Wetzels, S. et al. Methylglyoxal-derived advanced glycation endproducts accumulate in multiple sclerosis lesions. *Front. Immunol.* **10**, 855 (2019).
243. Herrmann, A. K. et al. Dimethyl fumarate alters intracellular Ca²⁺ handling in immune cells by redox-mediated pleiotropic effects. *Free Radic. Biol. Med.* **141**, 338–347 (2019).
244. Cavalcante de Moura, J. et al. The blockade of transient receptor potential ankyrin 1 (TRPA1) signalling mediates antidepressant and anxiolytic-like actions in mice. *Br. J. Pharmacol.* **171**, 4289–4299 (2014).
245. Borbély, É., Payrits, M., Hunyady, Á., Mező, G. & Pintér, E. Important regulatory function of transient receptor potential ankyrin-1 receptors in age-related learning and memory alterations in mice. *Geroscience* **41**, 643–654 (2019).
246. Lee, K. I., Lin, H. C., Lee, H. T., Tsai, F. C. & Lee, T. S. Loss of transient receptor potential ankyrin 1 channel deregulates emotion, learning and memory, cognition, and social behavior in mice. *Mol. Neurobiol.* **54**, 3606–3617 (2017).
247. US National Library of Medicine. Safety, tolerability, pharmacokinetic and pharmacodynamic effects of ODM-108: in healthy male volunteers (FIMTRIP). *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT02432664> (2017).
248. Payrits, M. et al. Genetic deletion of TRPA1 receptor attenuates amyloid beta-1-42 (A β ₁₋₄₂)-induced neurotoxicity in the mouse basal forebrain in vivo. *Mech. Ageing Dev.* **189**, 111268 (2020).
249. Sarycheva, T. et al. Antiepileptic drug use and the risk of stroke among community dwelling people with

- Alzheimer disease: a matched control study. *J. Am. Heart Assoc.* **7**, e009742 (2018).
250. Kim, J. et al. Ca²⁺-permeable TRPV1 pain receptor knockout rescues memory deficits and reduces amyloid- β and tau in a mouse model of Alzheimer's disease. *Hum. Mol. Genet.* **29**, 228–237 (2020).
251. Sakaguchi, R. & Mori, Y. Transient receptor potential (TRP) channels: biosensors for redox environmental stimuli and cellular status. *Free. Radic. Biol. Med.* **146**, 36–44 (2020).
252. Zhan, K.-Y., Yu, P. L., Liu, C.-H., Luo, J. H. & Yang, W. Detrimental or beneficial: the role of TRPM2 in ischemia/reperfusion injury. *Acta Pharmacol. Sin.* **27**, 4–12 (2016).
253. Fourgeaud, L. et al. Pharmacology of JNJ-28583113: a novel TRPM2 antagonist. *Eur. J. Pharmacol.* **853**, 299–307 (2019).
254. Dietz, R. M. et al. Reversal of global ischemia-induced cognitive dysfunction by delayed inhibition of TRPM2 ion channels. *Transl. Stroke Res.* **11**, 254–266 (2020).
255. Ko, S. Y. et al. Transient receptor potential melastatin 2 governs stress-induced depressive-like behaviors. *Proc. Natl Acad. Sci. USA* **116**, 1770–1775 (2019).
256. Xu, C. et al. Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. *Am. J. Med. Genet. B* **141B**, 36–43 (2006).
257. Jang, Y. et al. TRPM2, a susceptibility gene for bipolar disorder, regulates glycogen synthase kinase-3 activity in the brain. *J. Neurosci.* **35**, 11811–11823 (2015).
258. Krügel, U., Straub, I., Beckmann, H. & Schaefer, M. Primidone inhibits TRPM3 and attenuates thermal nociception in vivo. *Pain* **158**, 856–867 (2017).
This paper demonstrates that primidone, a drug used to treat essential tremor and seizures, blocks TRPM3 at clinically relevant doses.
259. Dymont, D. A. et al. De novo substitutions of TRPM3 causes intellectual disability and epilepsy. *Eur. J. Hum. Genet.* **27**, 1611–1618 (2019).
260. Earley, S., Waldron, B. J. & Brayden, J. E. Critical role of transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. *Circ. Res.* **95**, 922–929 (2004).
This is the first paper to demonstrate that TRPM4 regulates constriction of cerebral arteries.
261. Woo, S. K., Kwon, M. S., Ivanov, A., Gerzanich, V. & Simard, J. M. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (TRPM4) channel. *J. Biol. Chem.* **288**, 3655–3667 (2013).
262. Gerzanich, V. et al. De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injury. *Nat. Med.* **15**, 185–191 (2009).
263. Loh, K. P. et al. TRPM4 inhibition promotes angiogenesis after ischemic stroke. *Pflügers Arch.* **466**, 563–576 (2014).
264. Vorasayan, P. et al. Intravenous glibenclamide reduces lesional water uptake in large hemisphere infarction. *Stroke* **50**, 3021–3027 (2019).
265. US National Library of Medicine. Phase 3 study to evaluate the efficacy and safety of intravenous BILB093 (Glibenclamide) for severe cerebral edema following large hemispheric infarction (CHARM). *ClinicalTrials.gov* <https://www.clinicaltrials.gov/ct2/show/NCT02864953> (2021).
266. Schattling, B. et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. *Nat. Med.* **18**, 1805–1811 (2012).
267. Riccio, A. et al. Decreased anxiety-like behavior and Gαq/11-dependent responses in the amygdala of mice lacking TRPC4 channels. *J. Neurosci.* **34**, 3653–3667 (2014).
268. Riccio, A. et al. Essential role for TRPC5 in amygdala function and fear-related behavior. *Cell* **137**, 761–772 (2009).
269. Just, S. et al. Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice. *PLoS ONE* **13**, e0191225 (2018).
Riccio et al., Just et al. and Boehringer Ingelheim show that, as suggested by gene deletion studies, pharmacological inhibition of TRPC4 and TRPC5 channels is beneficial in murine models of anxiety and antidepressant.
270. Boehringer Ingelheim. Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders. <https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop> (2021).
271. Rasmus, K. C., O'Neill, C. E., Bachtell, R. K. & Cooper, D. C. Cocaine self-administration in rats lacking a functional *trpc4* gene. *F1000Research* **2**, 110 (2013).
272. Hong, C. et al. TRPC5 channel instability induced by depalmitoylation protects striatal neurons against oxidative stress in Huntington's disease. *Biochim. Biophys. Acta Mol. Cell. Res.* **1867**, 118620 (2020).
273. Zeevi, D. A., Frumkin, A. & Bach, G. TRPML and lysosomal function. *Biochim. Biophys. Acta* **1772**, 851–858 (2007).
274. Sun, M. et al. Mucopolidiosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. *Hum. Mol. Genet.* **9**, 2471–2478 (2000).
275. Wang, W. et al. Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation. *Proc. Natl Acad. Sci. USA* **112**, E1373–E1381 (2015).
276. Cortes, C. J. & La Spada, A. R. TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: molecular mechanisms, cellular processes, and emerging therapeutic options. *Neurobiol. Dis.* **122**, 83–93 (2019).
277. Song, J. X., Liu, J., Jiang, Y., Wang, Z. Y. & Li, M. Transcription factor EB: an emerging drug target for neurodegenerative disorders. *Drug Discov. Today* **26**, 164–172 (2021).
278. Tsunemi, T. et al. Increased lysosomal exocytosis induced by lysosomal Ca²⁺ channel agonists protects human dopaminergic neurons from α -synuclein toxicity. *J. Neurosci.* **39**, 5760–5772 (2019).
279. Schmiede, P., Fine, M. & Li, X. The regulatory mechanism of mammalian TRPMLs revealed by Cryo-EM. *FEBS J.* **285**, 2579–2585 (2018).
280. Chemical & Engineering News. Merck acquires Calport Therapeutics for its autophagy-boosting molecules. <https://cen.acs.org/business/mergers-&-acquisitions/Merck-acquires-Calport-Therapeutics-autophagy/97/i45> (2018).
281. Stock, K. et al. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. *Nat. Med.* **18**, 1252–1258 (2012).
282. Kiss, F., Pohóczyk, K., Szallasi, A. & Helyesi, Z. Transient receptor potential (TRP) channels in head-and-neck squamous cell carcinomas: diagnostic, prognostic, and therapeutic potentials. *Int. J. Mol. Sci.* **21**, E6374 (2020).
283. Chamoun, E. et al. The relationship between single nucleotide polymorphisms in taste receptor genes, taste function and dietary intake in pre-school aged children and adults in the Guelph family health study. *Nutrients* **10**, 990 (2018).
284. Bray, M. *Using capsaicin to lose weight: how it works.* <https://pepperscale.com/capsaicin-to-lose-weight/> (2019).
285. Wang, Y., Tang, C., Tang, Y., Yin, H. & Liu, X. Capsaicin has an anti-obesity effect through alterations in gut microbiota populations and short-chain fatty acid concentrations. *Food Nutr. Res.* **64**, <https://doi.org/10.29219/fnr.v64.3525> (2020).
286. Larsson, M. H., Håkansson, P., Jansen, F. P., Magnell, K. & Brodin, P. Ablation of TRPM5 in mice results in reduced body weight gain and improved glucose tolerance and protects from excessive consumption of sweet palatable food when fed high caloric diets. *PLoS ONE* **10**, e0138373 (2015).
287. Blednov, Y. A. et al. Perception of sweet taste is important for voluntary alcohol consumption in mice. *Genes. Brain Behav.* **7**, 1–13 (2008).
288. Reimúndez, A. et al. Deletion of the cold thermoreceptor TRPM8 increases heat loss and food intake leading to reduced body temperature and obesity in mice. *J. Neurosci.* **38**, 3643–3656 (2018).
289. Clemmensen, C. et al. Coordinated targeting of cold and nicotinic receptors synergistically improves obesity and type 2 diabetes. *Nat. Commun.* **9**, 4304 (2018).
290. Gram, D. X., Holst, J. J. & Szallasi, A. TRPV1: a potential therapeutic target in type 2 diabetes and comorbidities? *Trends Mol. Med.* **23**, 1002–1013 (2017).
291. Gram, D. X. et al. TRPV1 antagonists as novel anti-diabetic agents: regulation of oral glucose tolerance and insulin secretion through reduction of low-grade inflammation? *Med. Sci.* **7**, 82 (2019).
292. European Medicines Agency. A randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients with diabetes type 2. *EU Clinical Trials Register* <https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001880-22/LT> (2021).
293. Gaudet, R. A primer on ankyrin repeat function in TRP channels and beyond. *Mol. Biosyst.* **4**, 372–379 (2008).
294. Huang, Y., Fliegert, R., Guse, A. H., Lu, W. & Du, J. A structural overview of the ion channels of the TRPM family. *Cell Calcium* **85**, 102111 (2020).
295. Li, J. et al. The structure of TRPC ion channels. *Cell Calcium* **80**, 25–28 (2019).
296. Jin, P. et al. Electron cryo-microscopy structure of the mechanotransduction channel NOMPC. *Nature* **547**, 118–122 (2017).
297. Nahama, A., Ramachandran, R., Cisternas, A. F. & Ji, H. The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resinsiferatoxin to improve prognosis: a review. *Med. Drug Discov.* **5**, 100033 (2020).
298. Chao, Y.-K., Chang, S.-Y. & Grimm, C. Endo-lysosomal cation channels and infectious diseases. *Rev. Physiol. Biochem. Pharmacol.* https://doi.org/10.1007/112_2020_31 (2020).
299. Thakore, P. et al. Brain endothelial TRPA1 channels initiate neurovascular coupling. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.09.14.295600> (2020).
300. Tarantini, S. et al. Pharmacologically-induced neurovascular uncoupling is associated with cognitive impairment in mice. *J. Cereb. Blood Flow. Metab.* **35**, 1871–1881 (2015).
301. Diogo, D. et al. Phenome-wide association studies across large population cohorts support drug target validation. *Nat. Commun.* **9**, 4285 (2018).
302. Oh, S. J. et al. Ultrasonic neuromodulation via astrocytic TRPA1. *Curr. Biol.* **29**, 3386–3401 (2019).
303. Rezaayat, E. & Toostani, I. G. Review paper: a review on brain stimulation using low-intensity focused ultrasound. *Basic Clin. Neurosci.* **7**, 187–194 (2016).
304. Huffer, K. E., Aleksandrova, A. A., Jara-Oseguera, A., Forrest, L. R. & Swartz, K. J. Global alignment and assessment of TRP transmembrane domain structures to explore functional mechanisms. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.05.14.096792v1> (2020).
A recent comprehensive analysis of the structural similarities and differences of the transmembrane regions of TRP channels that reveals hot spots for interactions with modulatory chemical agents, including natural agonists, antagonists, tool compounds and drugs.

Acknowledgements

We thank N. Gavva [Takeda Pharma] for useful comments. This work was funded in part by NIH grant 1R21DC018497 (to R.G.).

Author contributions

All authors wrote the article. A.S. outlined the content and reviewed and edited the manuscript before submission.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Drug Discovery thanks Thomas Voets, Boyi Liu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2021